WO1993022680A1 - Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces - Google Patents
Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces Download PDFInfo
- Publication number
- WO1993022680A1 WO1993022680A1 PCT/US1993/003767 US9303767W WO9322680A1 WO 1993022680 A1 WO1993022680 A1 WO 1993022680A1 US 9303767 W US9303767 W US 9303767W WO 9322680 A1 WO9322680 A1 WO 9322680A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ligands
- group
- thiol
- groups
- slides
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/045—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers using devices to improve synthesis, e.g. reactors, special vessels
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00351—Means for dispensing and evacuation of reagents
- B01J2219/00364—Pipettes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00351—Means for dispensing and evacuation of reagents
- B01J2219/00364—Pipettes
- B01J2219/00367—Pipettes capillary
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00351—Means for dispensing and evacuation of reagents
- B01J2219/00364—Pipettes
- B01J2219/00367—Pipettes capillary
- B01J2219/00369—Pipettes capillary in multiple or parallel arrangements
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00351—Means for dispensing and evacuation of reagents
- B01J2219/00378—Piezo-electric or ink jet dispensers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00351—Means for dispensing and evacuation of reagents
- B01J2219/00389—Feeding through valves
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00351—Means for dispensing and evacuation of reagents
- B01J2219/00414—Means for dispensing and evacuation of reagents using suction
- B01J2219/00416—Vacuum
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00351—Means for dispensing and evacuation of reagents
- B01J2219/00427—Means for dispensing and evacuation of reagents using masks
- B01J2219/0043—Means for dispensing and evacuation of reagents using masks for direct application of reagents, e.g. through openings in a shutter
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00351—Means for dispensing and evacuation of reagents
- B01J2219/00427—Means for dispensing and evacuation of reagents using masks
- B01J2219/00432—Photolithographic masks
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00457—Dispensing or evacuation of the solid phase support
- B01J2219/00475—Sheets
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
- B01J2219/005—Beads
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
- B01J2219/00527—Sheets
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
- B01J2219/00527—Sheets
- B01J2219/00529—DNA chips
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
- B01J2219/00527—Sheets
- B01J2219/00531—Sheets essentially square
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
- B01J2219/00527—Sheets
- B01J2219/00536—Sheets in the shape of disks
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00585—Parallel processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/0059—Sequential processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00596—Solid-phase processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/00608—DNA chips
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/0061—The surface being organic
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/00612—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports the surface being inorganic
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/00623—Immobilisation or binding
- B01J2219/00626—Covalent
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/00623—Immobilisation or binding
- B01J2219/0063—Other, e.g. van der Waals forces, hydrogen bonding
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00659—Two-dimensional arrays
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/0068—Means for controlling the apparatus of the process
- B01J2219/00686—Automatic
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00709—Type of synthesis
- B01J2219/00711—Light-directed synthesis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
- B01J2219/00722—Nucleotides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
- B01J2219/00725—Peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/11—Compounds covalently bound to a solid support
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B60/00—Apparatus specially adapted for use in combinatorial chemistry or with libraries
- C40B60/14—Apparatus specially adapted for use in combinatorial chemistry or with libraries for creating libraries
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/815—Carrier is a synthetic polymer
- Y10S530/816—Attached to the carrier via a bridging agent
Definitions
- the present invention relates generally to methods and compositions useful for synthesizing and immobilizing oligonucleotides and other biological polymers on surfaces.
- the immobilized biological polymers which can be, for example, oligonucleotides or polypeptides, are useful in a variety of screening and assay methodologies.
- the present invention has applications in the fields of molecular biology, biochemistry, pharmacology, and medical diagnostic technology.
- U.S. Patent No. 4,562,157 describes a technique for attaching biochemical ligands to surfaces by attachment to a photochemically reactive arylazide. Irradiation of the azide creates a reactive nitrene that reacts irreversibly with macromolecules in solution resulting in the formation of a covalent bond. The high reactivity of the nitrene intermediate, however, results in both low coupling efficiencies and many potentially unwanted products due to nonspecific reactions.
- 4,681,870 describes a method for introducing free amino or carboxyl groups onto a silica matrix; the groups may subsequently be covalently linked to a protein in the presence of a carbodiimide.
- U.S. Patent No. 4,762,881 describes a method for attaching a polypeptide chain to a solid substrate by incorporating a light-sensitive unnatural amino acid group into the polypeptide chain and exposing the product to low-energy ultraviolet light.
- U.S. Patent No. 4,542,102 describes a method employing a photochemically active reagent (e.g., a psoralen compound) and a coupling agent, which attaches the photoreagent to the substrate. Photoactivation of the photoreagent binds a nucleic acid sequence to the substrate to five a sur ace-bound probe for a complementary oligonucleotide.
- a photochemically active reagent e.g., a psoralen compound
- a coupling agent which attaches the photoreagent to the substrate.
- Photoactivation of the photoreagent binds a nucleic acid sequence to the substrate to five a sur ace-bound probe for a complementary oligonucleotide.
- this method has low quantum yields in protic solvents, lacks spatial directability, and relies upon initial affinity between the photoreagent and nucleic acids to bind the nucleic acids to the surface prior to photoactivation.
- U.S. Patent No. 4,937,188 describes methods for forming maleimide-thiol linkages between a solid support and a molecular tether *
- thiol groups on sepharose are reacted with malei ide groups on an RNA polymer, which serves as the tether, and the RNA polymer is reacted with a protein, also via a maleimide-thiol linkage.
- maleimide groups immobilized on a solid support are reacted with sulfhydryl RNAse forming RNAse-agarose.
- 5,011,770 describes the use of a maleimide-thiol linkage to bind an -enzyme label to a binding protein, which in turn binds to single stranded DNA.
- the patent describes that the binding protein can also be attached to a solid support.
- the maleimide-thiol linkage is thus spatially separated from the actual linkage between the peptide and the solid support.
- PCT patent publication No. 90/07582 describes polyacrylamide supports on which are immobilized oligonucleotides. The oligonucleotides are derivatized at the 5'-terminus with thiol groups that are reacted with bromoacetyl groups on the polyacrylamide support during the immobilization process.
- 91/00868 discloses solid supports on which oligonucleotides are immobilized via a 5'- dithio linkage.
- the immobilization of biological polymers on solid supports has also had significant impact on drug discovery and medical diagnostic methods.
- One important invention in these fields is described in U.S. Patent No. 5,143,854, and the continuations-in-part of that application, Serial No. 624,120, filed December 6, 1990, and Serial No. 805,727, filed December 6, 1991, and in PCT patent publication Nos. 90/15070 to Pirrung et al. and 92/10092 to Fodor et al. , each of which is incorporated herein by reference.
- Novel methods and compositions of matter are provided for synthesizing and immobilizing oligonucleotides and other biological polymers on predefined regions of a surface of a soiid support.
- the methods involve attaching to the surface a thiol functional group protected with a photochemical protecting group so that the thiol has very low reactivity for other functional groups reactive with thiols.
- the protected thiol is convertible by irradiation .o a fully reactive thiol capable of immobilizing a desired biological polymer such as a nucleic acid, protein, polysaccharide, or a monomer building block for such polymers.
- Predefined regions of the surface are selectively irradiated to convert the protected thiols in the predefined regions to reactive thiol groups.
- the desired biological polymers (or monomer) subsequently can be immobilized on the activated regions of the surface.
- the spatial- addressability afforded by the method of the present invention allows the formation of patterned surfaces having preselected reactivities. For example, by using lithographic techniques known in the semiconductor industry, light can be directed to relatively small and precisely known locations on the surface. Thus, the present invention can be used to activate discrete, predetermined locations on the surface for attachment of biological polymers. The resulting surface will have a variety of uses. For example, direct binding assays can be performed in which nucleic acids in a sample can be simultaneously tested for affinity to a number of different oligonucleotide probes attached to the surface. Binding can be detected by a technique such as autoradiography when one of the binding moieties is radioactively labelled. Alternatively, fluorescence and optical measuring techniques can be used to detect the binding. By determining the locations and amount of label on the surface, one can simultaneously screen ligands for affinity to a plurality of anti-ligands.
- the present invention provides methods for building arrays of biomolecules using photolithographic techniques.
- the method obviates the need to separate reactants spatially, because the substrate is unreactive until specific sites are activated with light.
- the method involves the light-directed immobilization of oligonucleotides on a glass surface derivatized with a caged thiol reagent. The method can be used to fabricate large arrays of oligonucleotide probes.
- FIG. 1 presents the results of fluorescence excitation scanning of a slide on which a variety of activated oligonucleotides have been immobilized through covalent linkage to thiol groups on the slide; the results show that oligonucleotides activated with succinimidyl 6- maleimidylhexanoate are preferred for coupling to the thiol group-containing solid supports of the present invention (see Example 3) .
- FIG. 1 presents the results of fluorescence excitation scanning of a slide on which a variety of activated oligonucleotides have been immobilized through covalent linkage to thiol groups on the slide; the results show that oligonucleotides activated with succinimidyl 6- maleimidylhexanoate are preferred for coupling to the thiol group-containing solid supports of the present invention (see Example 3) .
- FIG. 1 presents the results of fluorescence excitation scanning of a slide on which a variety of activated oligon
- “Surface” is any generally two-dimensional structure on a solid substrate and may have steps, ridges, kinks, terraces, and the like without ceasing to be a surface.
- Predefined Region is a localized area on a surface which is or is intended to be activated.
- the predefined region may have any convenient shape, e.g. , circular, rectangular, elliptical, etc.
- Crosslinking Group is a bifunctional chemical entity that serves to connect a binding member to a surface. Usually, crosslinking groups are heterobifunctional and so have different chemical reactivities on either end of the linking group.
- Biological Polymer is a compound composed of monomeric units linked to one another that has biological activity or is reactive with a compound that has biological activity. Nucleic acids such as RNA and DNA are biological polymers, and peptides, proteins, and carbohydrates are also biological polymers.
- Anti-ligand is a molecule or a complex of molecules that has an affinity for a given ligand and can be immobilized on a predefined region of a surface. Anti-ligands may be naturally-occurring or synthetic molecules. Anti-ligands can be employed in an unaltered state or as aggregates with other species. Anti-ligands can be reversibly attached, covalently or noncovalently, to a. binding member, either directly or via a specific binding substance.
- Reversibly attached means that the binding of the anti-ligand (or specific binding member or ligand) is reversible and has, therefore, a substantially non ⁇ zero reverse, or unbinding, rate.
- reversible attachments can arise from noncovalent interactions, such as electrostatic forces, van der Waals forces, hydrophobic (i.e., entropic) forces-, and the like.
- reversible attachments also may arise from certain, but not all, covalent bonding reactions. Examples include, but are not limited to, attachment by the formation of hemiacetals, hemiketals, imines, acetals, ketals, and the like (See, Morrison et al. , "Organic Chemistry” , 2nd ed.
- anti-ligands examples include, but are not restricted to, receptors, such as cell membrane (such as those of B-cells, T-cells, and macrophages) receptors, polyclonal and monoclonal antibodi-es, and antisera reactive with specific antigenic determinants (such as on viruses, cells, or other materials) , hormones, drugs, oligonucleotides, peptides, enzymes, lectins, sugars, oligosaccharides, cells, cellular membranes, cellular membrane transport proteins, and organelles.
- receptors such as cell membrane (such as those of B-cells, T-cells, and macrophages) receptors, polyclonal and monoclonal antibodi-es, and antisera reactive with specific antigenic determinants (such as on viruses, cells, or other materials) , hormones, drugs, oligonucleotides, peptides, enzymes, lectins, sugars, oligosaccharides,
- Ligand is a solvated molecule that is recognized by a particular anti-ligand.
- ligands that can be investigated with the present invention include, but are not restricted to, agonists and antagonists for cell membrane receptors, toxins and venoms, antigenic determinants, such as viral epitopes, hormones, opiates, steroids, peptides, enzyme substrates, cofactors, drugs, lectins, sugars, oligonucleotides, oligosaccharides, and proteins.
- the present invention provides methods for forming predefined regions on a surface of a solid support, wherein the predefined regions comprise caged thiol groups that can be activated and then used to immobilize ligands and/or anti- ligands.
- the caged thiols attached to the surface can be selectively activated in predefined regions via covalent linkages.
- the activated thiols are then used to immobilize compounds, e.g., anti-ligands, on the predefined regions of the surface.
- the above procedure can be repeated at the same or different sites on the surface so as to provide a surface with a plurality of regions containing the same or different ligands or anti-ligands.
- screenings and assays for the ligands can be conducted in the regions of the surface containing the anti-ligands.
- the present method employs novel caged thiols attached to the substrate.
- Caged (unactivated) thiols have relatively low reactivity with functional groups typically reactive with thiols when compared with uncaged thiols.
- the caged thiols are protected until a suitable source of energy is applied to the regions of the surface to be activated.
- the caging groups labilize, thereby presenting the thiol.
- the energy source will -be light.
- the thiol groups on the surface Prior to activation, however, the thiol groups on the surface are "caged" with a protecting group.
- the protecting groups can either be attached to the compounds carrying the thiol functional group after those compounds have been attached to the surface or, more preferably, the protecting groups will be attached to the compounds carrying the thiol functional group prior to attaching the thiol functional group to the surface.
- Surface attachment of compounds carrying a thiol group or protected thiol group can be effected through the use of crosslinking groups.
- the crosslinking groups will usually, though not always, be- heterobifunctional chemical species having- a first reactivity that permits the crosslinking group to bind readily to the surface and a second reactivity that permits the crosslinking group to -bind- readily with compounds carrying a thiol group or protected thiol group.
- predefined regions on the surface can be activated for ultimate immobilization of anti-ligands in the predefined regions by selectively irradiating predefined regions to convert photoactivatable thiol groups in the predefined region to fully reactive thiol groups.
- the free protecting group may or may not undergo decomposition reactions.
- the byproducts of irradiation of the protecting group will usually be washed from the surface if the byproducts interfere with subsequent reactions.
- An immobilized anti-ligand on a surface will have a specific binding affinity for a particular ligand. If a surface comprising immobilized anti-ligands is exposed to a labeled ligand under conditions conducive to ligand binding to anti-ligand, then the resulting surface can be washed free of unbound ligand and analyzed for the presence of labeled ligand.
- the labels will provide markers localized at the predefined regions on the surface corresponding to the presence of anti- ligands for the ligand at those predefined regions.
- the presence of target ligand can be determined by analyzing appropriately for the loss or buildup of label on the predefined regions of the surface.
- a substrate for surface modification can be employed in the method of the invention.
- the substrate can be biological, nonbiological, organic, inorganic, or a combination of any of these materials, existing as particles, strands, precipitates, gels, sheets, tubing, spheres, containers, capillaries, -pads, slices, films, plates, slides, etc.
- the substrate can have any convenient shape, such as a disc, square, sphere, circle, etc.
- the substrate and the surface of the substrate preferably form a rigid support on which to carry out the reactions described herein.
- the substrate and the surface should also be chosen to provide appropriate light-absorbing characteristics.
- the substrate can be a polymerized Langmuir Blodgett film, functionalized glass, Si, Ge, GaAs, GaP, Si0 2 , SiN 4 , modified silicon, or any one of a wide variety of polymers such as (poly)tetrafluoroethylene, (poly)vinylidenedifluoride, or combinations thereof.
- Other substrate materials will be readily apparent to those of skill in the art upon review of this disclosure.
- the substrate is flat glass or single-crystal silicon with surface features of less than 10 angstroms. Surfaces on the solid substrate will usually, though not always, be composed of the same material as the substrate.
- the surface may be composed of any of a wide variety of materials, for example, polymers, plastics, resins, polysaccharides, silica or silica-based materials, carbon, metals, inorganic glasses, membranes, etc., provided only that caged thiols can be attached to the surface of the substrate.
- the surface will contain reactive groups, which could be carboxyl, amino, hydroxyl, or the like.
- the surface will be optically transparent and will have surface Si-OH functionalities, such as are found on silica surfaces.
- the surface of the substrate is preferably provided with a layer of crosslinking groups, although one of ordinary skill will understand that the crosslinking groups are not required elements of the invention.
- the crosslinking groups are preferably of sufficient length to permit thiol groups on the surface, as well as biological polymers covalently attached to the thiol groups, to interact freely with compounds in solution.
- Crosslinking groups can be selected from any suitable class of compounds, for example, aryl acetylenes, ethylene glycol oligomers containing two to ten monomer units, dia ines, diacids, amino acids, or combinations thereof. Other crosslinking groups may be used in view of this disclosure.
- Crosslinking groups can be attached to the surface by a variety of methods that are readily apparent to one having skill in the art. For example, crosslinking groups may be attached to the surface by siloxane bonds formed via reactions of crosslinking groups bearing trichlorosilyl or trisalkoxy groups with hydroxyl groups on the surface of the substrate.
- the crosslinking group used with a glass surface is t-BOC-aminopropyltriethoxysilane.
- the crosslinking groups can optionally be attached in an ordered array, i.e., as parts of the head groups in a polymerized Langmuir Blodgett film.
- the type of crosslinking group selected, and the method selected for attaching the crosslinking group to the surface will depend primarily on the crosslinking group having suitable reactivity with the compound carrying the thiol group desired to be attached to the surface.
- linking groups are preferably heterobifunctional, having one end adapted to react with the crosslinking groups and the other end adapted to react with the compound carrying the thiol group or another linking group.
- the linking groups may be attached by a variety of methods that are readily apparent to one skilled in the art, for instance, by esterification or amidation reactions of an activated ester of the linking group with a reactive hydroxyl or amine on the free end of the crosslinking group.
- a preferred linking group is N-BOC-6- aminocaproic acid (or N-BOC-6-aminohexanoic acid) attached by the BOP-activated ester. After deprotection to liberate the free amine terminus, another N-BOC-aminocaproic linker can be added. Attachment of crosslinking and linking groups to caged thiol compounds are discussed more fully below.
- the compound carrying the thiol group can be linked to the surface and later provided with protecting (caging) groups. More preferably, compounds carrying the thiol group will be attached to the surface in a protected form.
- the method chosen for linking the compound carrying the thiol group to the surface will depend upon the chemical properties of the compound carrying the thiol group selected for attachment to the surface.
- a preferred method for immobilizing the compound carrying the thiol group of the present invention involves chemical derivatization or activation of the caged compound carrying the thiol group prior to attachment to the surface or linker.
- This derivative or activated species is then reacted with functionalities on the substrate to give the desired linkage.
- a bifunctional crosslinking reagent such as diepoxide, which both activates the surface and provides a group that reacts with an activated compound carrying the thiol group.
- some surfaces can be activated with cyanogen bromide.
- an amine group on the surface can be coupled to a carboxyl group of a compound carrying the thiol group to effect the immobilization.
- the compound carrying the thiol group is a caged cysteine, or other thiol-containing synthetic or natural amino acid.
- Such compounds are useful in a wide variety of applications; for instance, one could carry out amino acid addition on either the amino or carboxyl groups of the protected cysteine and then, after photoactivation, derivatize the side chain of the cysteine residue.
- Such techniques will often employ different classes of protecting groups, so that one can modify the immobilized molecules at different reactive groups. These techniques include cyclization, where the cyclization step is controlled by the use of protecting groups on the two amino acid residues undergoing cyclization that are different from the protecting groups on amino acid residues that are not to be cyclized. See U.S. patent application Serial Nos. 796,727, filed November 22, 1991, and 946,239, filed September 16, 1992, each of which is incorporated herein by reference.
- protecting (caging) groups can be employed for modifying thiol groups to give the caged thiols of the present invention.
- the protecting groups should be sterically large enough to reduce the reactivity of the caged thiol with other substances to permit operability of the invention, although protecting groups utilizing other types of interactions, such as electronic, hydrophobic, etc., could be used.
- the selection of suitable caging groups will depend upon the size and chemical nature of the compound carrying the thiol group chosen and will- be readily apparent to one skilled in the art.
- the caging groups are photoactivatable. The properties and uses of photoreactive caged compounds have been reviewed. See McCray et al. , 1989, Ann. Rev. Biophvs. Biophys. Chem.
- the photosensitive cages will be activatable by low energy ultraviolet or visible light.
- the photosensitive protecting groups are aromatic compounds. Suitable photoremovable protecting groups are also described in, for example, Patchornik, 1970, J. Am- Chem. Soc. 92:6333. and Amit et al. , 1974, J. Orq. Chem. 3_9_:192, which are incorporated herein by reference. See also, Calbiochem Catalog (San Diego, CA, 1989), pp. 244-247, incorporated herein by reference.
- the photosensitive protecting group will be a nitro benzylic compound, such as o-nitrobenzyl or benzylsulfonyl groups.
- a nitro benzylic compound such as o-nitrobenzyl or benzylsulfonyl groups.
- 6- nitroveratryloxycarbonyl (NVOC) ; 6-nitropiperonyloxycarbonyl (NPOC) ; alpha, alpha-dimethyldimethoxybenzyloxycarbonyl (DDZ) , methyl 6-nitroveratryloxycarbonyl (MenVOC) , methyl-6- nitropiperonyloxycarbonyl (MeNPOC) , or 1-pyrenylmethyl is employed.
- photosensitive protecting groups are suitable for use in the present method.
- Some examples of acceptable photosensitive protecting groups are presented in Table l, below, together with their corresponding wavelengths for deprotection.
- NVOC 6-nitroveratryloxycarbonyl
- DDZ dimethyldimethoxybenzyloxycarbonyl
- NBOC nitrobenzyloxycarbonyl
- the radiation is UV, near IR, or visible light.
- the light source may be coherent or noncoherent.
- the exposed area is less than about 1 cm 2 or less than about 1 mm 2 .
- the irradiated area will be composed of a pattern of smaller, discrete irradiated areas, each of which is less than about 10,000 ⁇ m 2 or, more preferably, less than about 100 ⁇ m 2 .
- each individual synthesis site in the pattern is about 50 to 500
- Spaces between activated regions are not optional and, if used, will generally be greater than about 1 ⁇ m.
- Exposure of the surface to light will typically be carried out with a suitable mask using photolithographic techniques well known in the semiconductor industry and described in, for example, Sze, VLSI Technology. McGraw-Hill (1983) , which is incorporated herein by reference. See U.S. Patent No. 5,143,854.
- the mask is a transparent support material coated with a layer of opaque material (i.e., chrome- plated glass) . Portions of the opaque material are removed (or never deposited) , leaving a pattern that matches the precise pattern desired on the substrate surface.
- the mask can be a sheet or film composed of a non-transparent substance (i.e., anodized aluminum) ,- which sheet or film has been perforated in the desired pattern.
- the mask is brought into close proximity with or directly into contact with the surface. Openings -in the mask correspond to locations on the surface where one desires to photoremove protecting groups from thiol groups. Alignment may be performed using conventional alignment techniques in which alignment marks are used to overlay accurately successive masks with previous patterning steps. Other alignment techniques may be used, for example, interferometric techniques such as the one described in Flanders et al. , 1977, App. Phys. Lett. 3_l:426-428, which is incorporated herein by reference.
- contrast enhancement materials between the mask and the substrate.
- This contrast enhancement layer may comprise a molecule, such as -quinone diazide, which is decomposed by light.
- the light may be from a conventional incandescent source, an arc lamp, a laser, or the like. If noncoherent sources of light are used, one may utilize a thick or multi-layered mask to prevent spreading of the light on the substrate.
- lasers may be preferable, because lasers can more easily provide wavelengths particularly suited for a chromophore of the photosensitive group.
- the substrate may be rotated or oriented under a modulated laser or diode light source. Such techniques are discussed in, for example, U.S. Patent No. 4,719,615, which is incorporated herein by reference.
- the substrate may be irradiated either in contact with or not in contact with a solution but usually is irradiated in contact with a solution.
- the solution may contain reagents to prevent byproducts of irradiation from interfering with subsequent binding reactions.
- byproducts might include, for example, carbon dioxide, nitrosocarbonyl compounds, styrene derivatives, indole derivatives, and products of the photochemical reactions of such compounds.
- Reagents added to the solution may include, for example, acidic or basic buffers, thiols, substituted hydrazines and hydroxylamines, reducing agents (e.g., NADH,
- DTT dimethyl sulfoxide
- a given functional group e.g., aryl nitroso plus glyoxylic acid aryl form hydroxamate plus C0 2
- protecting groups will be selected that do not cause significant interference with the binding reactions.
- wash steps can be incorporated so that the byproducts do not interfere with the reactions.
- the light pattern can be changed and the same or a different anti- ligand, ligand, polymer, or monomer can be localized at other discrete sites on the- surface.
- Anti-ligands that are nucleic acids are especially preferred.
- a plurality of nucleic acid anti-ligands are immobilized on a surface by first attaching photoreactive caged thiols to the surface. The caged thiols on a predefined region of the surface are exposed to light to give reactive thiol groups.
- the reactive thiol groups on the predefined region are then incubated with a first activated nucleic acid anti-ligand to be immobilized, the surface is washed free of unreacted nucleic acid, and the surface is incubated with a desired ligand.
- the exact incubation conditions e.g., time, temperature, pH, etc., will depend upon the species used and will be readily apparent to one skilled in the art.
- the above steps can be repeated on a different region of the surface with a different nucleic acid. In this fashion, a small, dense array of-, e.g., oligonucleotide probes, can be prepared.
- a surface prepared according to the methods described above can be used to screen for ligands having high affinity for immobilized anti-ligands. Screening can be performed by immobilizing a plurality of anti-ligands on predefined regions of a surface by the methods described above. A solution containing a marked (labelled) ligand is introduced ' to the surface and incubated for a suitable period of time. The surface is then washed free of unbound ligand, and the anti- ligands having high affinity for the ligand are identified by identifying those regions on the surface where markers are located. Suitable markers include, but are not limited to, radiolabels, chromophores, fluorophores, chemiluminescent moieties, and transition metals.
- the marker is a radioactive label, such as 32 P.
- the marker on the surface is exposed to X-ray film, which is developed and read out on a scanner. An exposure time in the range of 1 to 24 hours is typical. Fluorescence detection using a fluorophore label, such as fluorescein, attached to the ligand will usually require much shorter exposure times.
- the presence of ligands may be detected using a variety of other techniques, such as an assay with a labelled enzyme, antibody, or the like. Other techniques using various marker systems for detecting bound ligand will be readily apparent to those skilled in the art. See U.S. Patent No. 5,143,854.
- a substrate prepared as discussed above can be exposed to a solution containing one or more ligands such as nucleic acids.
- the ligand can be labeled in any of a variety of ways, but in one embodiment, the ligand is an oligonucleotide probe having a radioactive (or other) label.
- the ligand nucleic acid binds (hybridizes) with high affinity to an immobilized nucleic acid previously localized on the surface and to the complementary labeled probe. Hybridization conditions are known in the art, but the arrays of the invention allow one to use very small volumes of target- containing solution for analysis.
- micropipettes to deliver very small volumes (i.e., 1 to 5 ⁇ L or less) very precisely, one can allow evaporation to drive hybridization.
- the surface is placed proximate to X-ray film, if a radioactive label is employed, to identify the nucleic acids on the surface complementary to the nucleic acid ligand.
- a fluorescent label can be used, and detection can be accomplished with a charge-coupled device (CCD) , fluorescence microscopy, or laser scanning.
- CCD charge-coupled device
- fluorescence microscopy or laser scanning.
- a related labeling technique involves the use of a labeled probe in solution that will hybridize with the target nucleic acid ligand without interferring with hybridization of the ligand to the immobilized probe.
- the capture probes are designed to have a sequence complementary to the target sequence to be detected and a sequence complementary to an immobilized probe located at one or more discrete locations on the surface of the substrate.
- either the capture probe is labeled or another labeled probe complementary to the target sequence to be detected is employed.
- This system allows the hybridization of probe to target sequence to be carried out in solution, because the immobilized probe array does not have to be (but can be, if desired) present in the reaction mixture during hybridization of the capture probe to the target sequence.
- Quantitative assays for ligand concentrations can also be performed according to the present invention.
- a direct assay method the surface containing localized anti- ligands prepared as described above is incubated with a solution containing a labeled ligand for a suitable period of time. The surface is then washed free of unbound ligand. The amount of label present at predefined regions of the surface is then measured and can be related to the amount of ligand in solution.
- Methods and conditions for performing such assays are well-known and are presented in, for example, Hood et al., Immunology (Benjamin/Cummings 1978) and Harlow et al..
- a competitive assay method can also be employed using the methods and reagents of the present invention.
- Such a method involves immobilizing anti-ligands on predefined regions of a surface as described above. An unmarked ligand is then bound to anti-ligands on the surface having specific binding affinity for the ligand. A solution containing marked ligand is then introduced to the surface and incubated for a suitable time. The surface is then washed free of unbound reagents, and the amount of marker remaining on the surface is measured.
- marked and unmarked ligand can be exposed to the surface simultaneously.
- the amount of marker remaining on predefined regions of the surface can be related to the amount of unknown ligand in solution.
- the invention is illustrated in the Examples below primarily with reference to the identification of specific nucleic acid sequences in a sample. The invention will, however, find many other uses.
- the invention can be used in information storage (e.g., on optical disks), production of molecular electronic devices, production of stationary phases in separation sciences, and in immobilization of- cells, proteins, lectins, nucleic acids, polysaccharides and the like in any desired pattern on a surface via molecular recognition of a specific anti-ligand linked via a thiol group to a surface of a substrate.
- Example 1 Preparation of Substrate and Thiol-derivatized Surface A. Preparation of Substrate Surface
- Commercially available glass microscope slides for example, 1" x 3" smooth cut, 0.7 mm thick, anti-scratch coated slides or 2" x 3" smooth cut, 0.7 -mm thick, anti-scratch coated slides from Erie Scientific
- t-BOC- aminopropyltriethoxy silane in substantial accordance with the procedure described in J. Chromatography 97:33 (1974), incorporated herein by reference.
- the slides were cleaned by soaking in 10% Micro detergent (Baxter) , individually scrubbed, and immersed in deionized water.
- the slides were then subjected to a 10 minute sonication in a 70°C solution of 10% Micro detergent and rinsed ten times with deionized water. This process was followed by a three minute immersion in a 70°C solution of 10% (w/v) NaOH.
- the slides were then rinsed ten times with deionized water, and then immersed for one minute in 1% HC1.
- the slides were then again rinsed ten times with deionized water, and then subjected to another 10 minute sonication in 70°C deionized water, after which the slides were rinsed three to four times in deionized water.
- the slides were then ethanol rinsed and dried with nitrogen or argon.
- the slides were then inspected visually for spots and scratches in a yellow light with a black background, and any slides that were scratched- or spotted or that still retained the anti-scratch coating were either discarded or recleaned.
- An alternate or additional cleaning procedure is carried out as follows.
- the slides are loaded into teflon racks and subjected to a thirty minute immersion in a solution composed of Nochromix (Aldrich) with 36 g/L of concentrated sulfuric acid (which can be regenerated if discolored) that has been filtered (glass fiber filter) to remove particulate matter. Occasional agitation is provided during the thirty minute immersion step.
- the slides are then rinsed for one minute in deionized water with vigorous agitation.
- the slides are then placed for ten minutes in a rinse tank with 14 psi argon or nitrogen bubbling, a full open deionized water tap, and occasional agitation.
- the slides are then immersed for three minutes in a 70°C solution of 10% (w/v) NaOH, followed by a one minute rinse with deionized water and vigorous agitation, followed by a ten minute rinse in a rinse tank.
- the slides are then immersed for one minute in 1% HC1 and then rinsed for five minutes in a rinse tank.
- the slides are then ethanol rinsed, dried with nitrogen or argon, and inspected visually for spots and scratches.
- the t-BOC aminopropyl derivatization is carried out as follows.
- the slides are loaded into plastic staining jars, with about nine slides per jar.
- the slides are completely dry when placed in the staining jars, and the silation reagents are added as follows.
- the silation reagent is a premixed solution of a 1:10 molar ratio of t-BOC- aminopropyltriethoxysilane:methyltriethoxysilane (i.e., 1 L of t-BOC-aminopropyltriethoxysilane and 5.86 mL of methyltriethoxysilane, which is kept anhydrous and stored under argon) .
- the silation reagent is diluted to 1% (v/v) in dichloromethane (DCM) , mixed well, and 60 mL of the diluted silation reagent are added to each jar.
- the jars are capped and incubated overnight at room temperature.
- the slides are removed from the jar, rinsed first with DCM and then with toluene and then dried immediately with argon.
- the slides are then loaded onto glass drying racks, inspected for streaks, and allowed to stand for approximately thirty minutes.
- the slides are then baked for one hour in a 100°C oven with the glass racks in metal trays covered with foil. The oven should be no hotter than 110°C.
- the slides are then cooled and optionally numbered with an engraving tool.
- DIEA diisopropylethylamine
- Nitroveratrylthiolpropionic acid was prepared in substantial accordance with the protocols set forth in Patchornik et al.. , 21 Oct. 1970, J. Am « Chem. Soc. 92(21) :6333- 6335, incorporated herein by reference.
- the aqueous phase was separated, acidified with 1 N HC1, extracted with methylene chloride, and then the organic layer was dried (Na 2 S0 4 ) , and ihen rotary evaporated to dryness. About 0.54 g of nitroveratrylthiolpropionic acid was obtained.
- the product can be further purified by dissolving the product in ethanol, adding five volumes of water, and collecting the needle-shaped crystals by filtration.
- Example 2 Coupling of Fluorescein Maleimide to Substrate Surface
- a glass microscope slide- prepared as described in Example IC was mounted on a flow cell and illuminated through a 500 ⁇ m 500 ⁇ m checkerboard-pattern mask (Photo Sciences Inc. , Torrance, CA) using broad-band UV/blue light. This pattern was repeated in triplicate on each slide, and the illumination was carried out so that one region underwent a four minute photolysis, a second region underwent a two minute hydrolysis, and a third region underwent a one minute photolysis.
- a 500 ⁇ m 500 ⁇ m checkerboard-pattern mask Photo Sciences Inc. , Torrance, CA
- the light source was a 500 W Mercury arc lamp (Oriel Model 87330) equipped with a 350 nm - 450 nm dichroic reflector that produced actinic light having an intensity of 12 mW/cm 2 as measured through a 360 nm bandpass filter.
- the derivatized surface was photolyzed in flowing dioxane for 15 minutes and then rinsed in ethanol and dried with argon. About 4.3 mg of fluorescein maleimide (Molecular
- Probe were dissolved in 10 mL of warm DMF to obtain a one mM solution of fluorescein maleimide. This solution was allowed to cool to room temperature, and then the slide was immersed in the solution and incubated at room temperature for two hours with gentle agitation. The slide was then removed from the solution and rinsed sequentially with DMF, ethanol, methylene chloride, and again with ethanol, and then the slide was dried with argon.
- the slide was examined with a scanning fluorescence microscope (Zeiss Axioskop equipped with a Newport Model PM500- C motion controller, a Spectra-Physics Model 2020 argon-ion laser producing a 488 nm excitation light; and a 520 nm long- pass emission filter) interfaced with a photon-counting device (Hamamatsu Model 9403-02 photomultiplier; Stanford Research Systems Model SR445 amplifier and Model SR430 multichannel sealer, IBM compatible PC) to generate a two-dimensional image consisting of fluorescence intensity data as a function of x,y position.
- a scanning fluorescence microscope Zeiss Axioskop equipped with a Newport Model PM500- C motion controller, a Spectra-Physics Model 2020 argon-ion laser producing a 488 nm excitation light; and a 520 nm long- pass emission filter
- a photon-counting device Hamatsu Model 9403-02 photo
- Example 3 Coupling of Oligonucleotides with Thiol-reactive Groups to Substrate Surface This example shows the results of a test for the effectiveness of several different thiol-reactive groups that, when attached to an oligonucleotide, enable covalent coupling to thiol-derivatized glass slides.
- a 5*-fluoresceinated 3'-C6-amino oligonucleotide probe (designated CAP2, which was prepared using the Clonetech reagent 3*-C6-amino-modifier-CPG) was activated with the following heterobifunctional reagents: (1) succinimidyl bromoacetate (BrAc-NHS) ; (2) succinimidyl iodoacetate (IAc- NHS) ; (3) succinimidyl 6-( (iodoacetyl)amino)hexanoate (SIAX) ; (4) succinimidyl 6-(6-(( (iodoacetyl)amino)hexanoyl)amino)- hexanoate (SIAXX) ; and (5) succinimidyl 6-maleimidylhexanoate (EMCS) .
- succinimidyl bromoacetate BrAc-NHS
- the reaction was incubated at 25°C for 30 minutes, and the resulting modified oligonucleotide was desalted on a G-25 spin column (unbuffered water) and then used without further purification at a concentration of about 100 ⁇ M (determined spectrophotometrically) .
- Polyacrylamide gel electrophoresis assays after quenching- with a fluorescent thiol indicated that about 75% of the oligonucleotides were modified in the.reaction.
- This example shows the results of the addition of a variety of additives on the coupling efficiency of a maleimide- activated, 5'-fluoresceinated oligonucleotide to thiol- derivatized slides.
- the 5*-fluoresceinated 3'—C6-amino oligonucleotide was activated with succinimidyl 6- maleimidylhexanoate and applied to a freshly photolyzed slide as a solution in water in substantial accordance with the procedure set forth in Example 3.
- Example 5 Hybridization of Nucleic Acids to Immobilized Oligonucleotide
- Two glass slides prepared in accordance with the procedures set forth in Examples 3 and 4 were tested for ability to hybridize specifically with a complementary oligonucleotide.
- the two slides differed with respect to the additive present during the coupling reaction; one slide was coupled to oligonucleotide in the presence of LiCl, the other in the presence of DTAB.
- the slides were prehybridized individually in heat sealed bags at 56°C with a solution composed of 6X SSC, 6X Denhardt's solution, 0.5% SDS, and 100 ⁇ g/mL of sheared, denatured, salmon sperm DNA.
- the hybridization reaction was carried out at 53.5°C (T M minus 5°C) in prehybridization buffer containing 1 pmole of a 32 P-end labeled 60mer probe (specific activity of 1.5 x 10 8 CPM/ ⁇ g) containing a 30 nucleotide segment perfectly complementary to the covalently coupled oligonucleotide probe.
- the hybridized slides were evaluated in a beta plate counter and by autoradiography.
- hybridization acceleration reagents that can be employed in the method of the present invention include Al protein, RecA protein, SSB, dextran sulfate, ficoll, phenol, and detergent.
- Prehybridization was carried out for 15 minutes at 53.5°C, and then 100 ⁇ L of 10 mg/mL salmon sperm DNA was added to the slides together with 10 ⁇ L (one pmole) of the labeled probe.
- the hybridization reaction was carried out at 53.5°C for one hour.
- the slides were washed and then allowed to expose XAR film overnight at -70°c.
- Example 2 A slide prepared as described in Example 1 is photolyzed under dioxane and then rinsed with ethanol and dried under a nitrogen stream. The slide is clamped to a template that forms a well over the photolyzed area, and 20 ⁇ L of a 100 ⁇ M solution of 3•-EMCS-activated probe CAP2 ( ⁇ '-CCAACTCTTTTTCCGAAGGTAACTGGCTTC [SEQ. ID NO. 1]) in unbuffered water and HEPES/EDTA/DTAB buffer are added to the well.
- 3•-EMCS-activated probe CAP2 ⁇ '-CCAACTCTTTTTCCGAAGGTAACTGGCTTC [SEQ. ID NO. 1]
- the slide and template are then incubated at room temperature for two hours, the reaction is quenched by the addition of N-ethyl maleimide, and the slide is rinsed liberally first with water and then with dioxane. The slide is then re-photolyzed to activate a different region on the slide and then coupled to 3'-ECMS-activated probe CAP5 (5 1 -
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
Abstract
Substrates with surfaces comprising compounds with thiol functional groups protected with a photoremovable protecting group can be used to construct arrays of immobilized anti-ligands, such as oligonucleotide probes or other biological polymers. The arrays can be used in assays to detect the presence of complementary nucleic acids in a sample. Spatially addressed irradiation of predefined regions on the surface permits immobilization of oligonucleotides and other biological polymers at the activated regions on the surface. Cycles of irradiation on different regions of the surface and immobilization of different anti-ligands allow formation of an immobilized matrix of anti-ligands at defined sites on the surface. The immobilized matrix of anti-ligands permits simultaneous screenings of a liquid sample for ligands having high affinities for certain anti-ligands of the matrix.
Description
SPATIALLY-ADDRESSABLE IMMOBILIZATION OF OLIGONUCLEOTIDES AND OTHER BIOLOGICAL POLYMERS ON SURFACES
BACKGROUND OF THE INVENTION Field of the Invention The present invention relates generally to methods and compositions useful for synthesizing and immobilizing oligonucleotides and other biological polymers on surfaces. The immobilized biological polymers, which can be, for example, oligonucleotides or polypeptides, are useful in a variety of screening and assay methodologies. The present invention has applications in the fields of molecular biology, biochemistry, pharmacology, and medical diagnostic technology.
Description of Related Art Many different methods are known for attaching biological molecules to solid supports. See generally, Affinity Techniques. Enzyme Purification: Part B, Meth. Enz. 34 (ed. W.B. Jakoby and M. ilchek, Acad. Press, NY 1974) and Immobilized Biochemicals and Affinity Chromatocrraphv, Adv. Exp. Med. Biol. 42 (ed. R. Dunlap, Plenum Press, NY 1974) , incorporated herein by reference. The patent literature also describes a number of different methods for attaching biological molecules to solid supports. For example, U.S. Patent No. 4,282,287 describes a method for modifying a polymer surface through the successive application of multiple layers of biotin, avidin, and extenders. U.S. Patent No. 4,562,157 describes a technique for attaching biochemical ligands to surfaces by attachment to a photochemically reactive arylazide. Irradiation of the azide creates a reactive nitrene that reacts irreversibly with macromolecules in solution resulting in the formation of a covalent bond. The high reactivity of the nitrene intermediate, however, results in both low coupling efficiencies and many potentially unwanted products due to nonspecific reactions.
U.S. Patent No. 4,681,870 describes a method for introducing free amino or carboxyl groups onto a silica matrix; the groups may subsequently be covalently linked to a protein in the presence of a carbodiimide. Also, U.S. Patent No. 4,762,881 describes a method for attaching a polypeptide chain to a solid substrate by incorporating a light-sensitive unnatural amino acid group into the polypeptide chain and exposing the product to low-energy ultraviolet light.
A variety of techniques have also been developed for attaching oligonucleotides to surfaces. For example, U.S. Patent No. 4,542,102 describes a method employing a photochemically active reagent (e.g., a psoralen compound) and a coupling agent, which attaches the photoreagent to the substrate. Photoactivation of the photoreagent binds a nucleic acid sequence to the substrate to five a sur ace-bound probe for a complementary oligonucleotide. However, this method has low quantum yields in protic solvents, lacks spatial directability, and relies upon initial affinity between the photoreagent and nucleic acids to bind the nucleic acids to the surface prior to photoactivation.
U.S. Patent No. 4,937,188 describes methods for forming maleimide-thiol linkages between a solid support and a molecular tether* In one example, thiol groups on sepharose are reacted with malei ide groups on an RNA polymer, which serves as the tether, and the RNA polymer is reacted with a protein, also via a maleimide-thiol linkage. In another example, maleimide groups immobilized on a solid support are reacted with sulfhydryl RNAse forming RNAse-agarose. U.S. Patent No. 5,011,770 describes the use of a maleimide-thiol linkage to bind an -enzyme label to a binding protein, which in turn binds to single stranded DNA. The patent describes that the binding protein can also be attached to a solid support. The maleimide-thiol linkage is thus spatially separated from the actual linkage between the peptide and the solid support. PCT patent publication No. 90/07582 describes polyacrylamide supports on which are immobilized oligonucleotides. The oligonucleotides are derivatized at the 5'-terminus with thiol groups that are reacted with bromoacetyl
groups on the polyacrylamide support during the immobilization process. PCT patent publication No. 91/00868 discloses solid supports on which oligonucleotides are immobilized via a 5'- dithio linkage. The immobilization of biological polymers on solid supports has also had significant impact on drug discovery and medical diagnostic methods. One important invention in these fields is described in U.S. Patent No. 5,143,854, and the continuations-in-part of that application, Serial No. 624,120, filed December 6, 1990, and Serial No. 805,727, filed December 6, 1991, and in PCT patent publication Nos. 90/15070 to Pirrung et al. and 92/10092 to Fodor et al. , each of which is incorporated herein by reference. In brief, these publications describe methods and reagents for synthesizing very large numbers of different compounds, particularly biological polymers, in distinct and spatially-addressable locations in a very small area on a substrate. Another description of the method is found in Fodor et al. , 15 Feb. 1991, Science 251:767-773- and the integration of the method with other drug discovery methods is described in Dower and Fodor, 1991, Ann. Rep. Med. Chem. ,26:271-280. A related method uses a photoactivateable derivative of biotin as the agent for immobilizing a biological polymer of interest onto a solid support; see PCT patent publication No. 91/07087 to Barrett et al. , incorporated herein by reference.
Recent approaches to genetic analysis are increasingly placing importance on performing parallel hybridizations in an array format. Applications of the parallel hybridization format include generating diagnostic arrays for tissue typing or diagnosis of genetic disorders
(see PCT patent publication No. 89/11548, incorporated herein by reference) , DNA sequencing by hybridization, DNA fingerprinting, and genetic mapping (see PCT patent publication Nos. 92/10587 and 92/10588, each of which is incorporated herein by reference; see also Khrapko et al. , 1991, J. DNA,, Seq. Map. .1:375-388). In these applications of probe arrays, the information content of the array increases as the number of probes is increased. The size limit of the array is dictated
by the ability to automate and miniaturize the fabrication of the array.
Thus, there exists a need for improved methods for attaching a broad range of anti-ligands to predefined regions of a solid support surface. The methods should efficiently provide stable attachment of selected polymers to the activated surface regions, yet attachment should be restricted to the activated regions. The present invention fulfills these and other needs.
SUMMARY OF THE INVENTION Novel methods and compositions of matter are provided for synthesizing and immobilizing oligonucleotides and other biological polymers on predefined regions of a surface of a soiid support. The methods involve attaching to the surface a thiol functional group protected with a photochemical protecting group so that the thiol has very low reactivity for other functional groups reactive with thiols. The protected thiol is convertible by irradiation .o a fully reactive thiol capable of immobilizing a desired biological polymer such as a nucleic acid, protein, polysaccharide, or a monomer building block for such polymers. Predefined regions of the surface are selectively irradiated to convert the protected thiols in the predefined regions to reactive thiol groups. The desired biological polymers (or monomer) subsequently can be immobilized on the activated regions of the surface.
The spatial- addressability afforded by the method of the present invention allows the formation of patterned surfaces having preselected reactivities. For example, by using lithographic techniques known in the semiconductor industry, light can be directed to relatively small and precisely known locations on the surface. Thus, the present invention can be used to activate discrete, predetermined locations on the surface for attachment of biological polymers. The resulting surface will have a variety of uses. For example, direct binding assays can be performed in which nucleic acids in a sample can be simultaneously tested for affinity to a number of different oligonucleotide probes
attached to the surface. Binding can be detected by a technique such as autoradiography when one of the binding moieties is radioactively labelled. Alternatively, fluorescence and optical measuring techniques can be used to detect the binding. By determining the locations and amount of label on the surface, one can simultaneously screen ligands for affinity to a plurality of anti-ligands.
Thus, the present invention provides methods for building arrays of biomolecules using photolithographic techniques. The method obviates the need to separate reactants spatially, because the substrate is unreactive until specific sites are activated with light. In one embodiment, the method involves the light-directed immobilization of oligonucleotides on a glass surface derivatized with a caged thiol reagent. The method can be used to fabricate large arrays of oligonucleotide probes.
A further understanding of the nature and advantages of the invention may be realized by reference to the remaining portions of the specification.
BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 presents the results of fluorescence excitation scanning of a slide on which a variety of activated oligonucleotides have been immobilized through covalent linkage to thiol groups on the slide; the results show that oligonucleotides activated with succinimidyl 6- maleimidylhexanoate are preferred for coupling to the thiol group-containing solid supports of the present invention (see Example 3) . FIG. 2 presents the results of fluorescence excitation scanning of a slide on which oligonucleotides have been immobilized through covalent linkage to thiol groups on the slide in the presence of different additives; the results show that the anionic, zwitterionic, and neutral detergents do not appear to enhance coupling efficiency; the salts TMAC (trimethylammonium chloride) and LiCl give a moderate enhancement in coupling efficiency; and the cationic detergent
DTAB causes a large enhancement in coupling efficiency at relatively low concentrations (see Example 4) .
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The following terms have the following meanings and abbreviations as used herein:
"Surface" is any generally two-dimensional structure on a solid substrate and may have steps, ridges, kinks, terraces, and the like without ceasing to be a surface.
"Predefined Region" is a localized area on a surface which is or is intended to be activated. The predefined region may have any convenient shape, e.g. , circular, rectangular, elliptical, etc. "Crosslinking Group" is a bifunctional chemical entity that serves to connect a binding member to a surface. Usually, crosslinking groups are heterobifunctional and so have different chemical reactivities on either end of the linking group. "Biological Polymer" is a compound composed of monomeric units linked to one another that has biological activity or is reactive with a compound that has biological activity. Nucleic acids such as RNA and DNA are biological polymers, and peptides, proteins, and carbohydrates are also biological polymers. Synthetic, non-naturally occurring monomers can be used to construct a biological polymer. For instance, carbamates, phosphonates, sulfonamides, and sulfoxides are examples of monomers that can be used to construct biological polymers. "Anti-ligand" is a molecule or a complex of molecules that has an affinity for a given ligand and can be immobilized on a predefined region of a surface. Anti-ligands may be naturally-occurring or synthetic molecules. Anti-ligands can be employed in an unaltered state or as aggregates with other species. Anti-ligands can be reversibly attached, covalently or noncovalently, to a. binding member, either directly or via a specific binding substance. "Reversibly attached" means that the binding of the anti-ligand (or specific binding member or
ligand) is reversible and has, therefore, a substantially non¬ zero reverse, or unbinding, rate. Such reversible attachments can arise from noncovalent interactions, such as electrostatic forces, van der Waals forces, hydrophobic (i.e., entropic) forces-, and the like. Furthermore, reversible attachments also may arise from certain, but not all, covalent bonding reactions. Examples include, but are not limited to, attachment by the formation of hemiacetals, hemiketals, imines, acetals, ketals, and the like (See, Morrison et al. , "Organic Chemistry" , 2nd ed. , Ch. 19 (1966), which is incorporated herein by reference) . Examples of anti-ligands that can be employed in the practice of the present invention include, but are not restricted to, receptors, such as cell membrane (such as those of B-cells, T-cells, and macrophages) receptors, polyclonal and monoclonal antibodi-es, and antisera reactive with specific antigenic determinants (such as on viruses, cells, or other materials) , hormones, drugs, oligonucleotides, peptides, enzymes, lectins, sugars, oligosaccharides, cells, cellular membranes, cellular membrane transport proteins, and organelles.
"Ligand" is a solvated molecule that is recognized by a particular anti-ligand. Examples of ligands that can be investigated with the present invention include, but are not restricted to, agonists and antagonists for cell membrane receptors, toxins and venoms, antigenic determinants, such as viral epitopes, hormones, opiates, steroids, peptides, enzyme substrates, cofactors, drugs, lectins, sugars, oligonucleotides, oligosaccharides, and proteins.
The present invention provides methods for forming predefined regions on a surface of a solid support, wherein the predefined regions comprise caged thiol groups that can be activated and then used to immobilize ligands and/or anti- ligands. The caged thiols attached to the surface can be selectively activated in predefined regions via covalent linkages. The activated thiols are then used to immobilize compounds, e.g., anti-ligands, on the predefined regions of the surface. The above procedure can be repeated at the same or different sites on the surface so as to provide a surface with
a plurality of regions containing the same or different ligands or anti-ligands. When the anti-ligands have a particular affinity for one or more ligands, screenings and assays for the ligands can be conducted in the regions of the surface containing the anti-ligands.
The present method employs novel caged thiols attached to the substrate. Caged (unactivated) thiols have relatively low reactivity with functional groups typically reactive with thiols when compared with uncaged thiols. Thus, the caged thiols are protected until a suitable source of energy is applied to the regions of the surface to be activated. Upon application of a suitable energy source, the caging groups labilize, thereby presenting the thiol. Typically, the energy source will -be light. Once the thiols on the surface are activated, the thiols can be attached to and reacted with a biological polymer of interest, typically a nucleic acid or other anti-ligand.
Prior to activation, however, the thiol groups on the surface are "caged" with a protecting group. The protecting groups can either be attached to the compounds carrying the thiol functional group after those compounds have been attached to the surface or, more preferably, the protecting groups will be attached to the compounds carrying the thiol functional group prior to attaching the thiol functional group to the surface. Surface attachment of compounds carrying a thiol group or protected thiol group can be effected through the use of crosslinking groups. The crosslinking groups will usually, though not always, be- heterobifunctional chemical species having- a first reactivity that permits the crosslinking group to bind readily to the surface and a second reactivity that permits the crosslinking group to -bind- readily with compounds carrying a thiol group or protected thiol group.
As noted above, predefined regions on the surface can be activated for ultimate immobilization of anti-ligands in the predefined regions by selectively irradiating predefined regions to convert photoactivatable thiol groups in the predefined region to fully reactive thiol groups. The free protecting group may or may not undergo decomposition
reactions. The byproducts of irradiation of the protecting group will usually be washed from the surface if the byproducts interfere with subsequent reactions.
An immobilized anti-ligand on a surface will have a specific binding affinity for a particular ligand. If a surface comprising immobilized anti-ligands is exposed to a labeled ligand under conditions conducive to ligand binding to anti-ligand, then the resulting surface can be washed free of unbound ligand and analyzed for the presence of labeled ligand. The labels will provide markers localized at the predefined regions on the surface corresponding to the presence of anti- ligands for the ligand at those predefined regions. The presence of target ligand can be determined by analyzing appropriately for the loss or buildup of label on the predefined regions of the surface.
To prepare the surface comprising immobilized biological polymers of the invention, one first selects a substrate for surface modification. Virtually any solid substrate can be employed in the method of the invention. The substrate can be biological, nonbiological, organic, inorganic, or a combination of any of these materials, existing as particles, strands, precipitates, gels, sheets, tubing, spheres, containers, capillaries, -pads, slices, films, plates, slides, etc. The substrate can have any convenient shape, such as a disc, square, sphere, circle, etc. The substrate and the surface of the substrate preferably form a rigid support on which to carry out the reactions described herein.
The substrate and the surface should also be chosen to provide appropriate light-absorbing characteristics. For instance, the substrate can be a polymerized Langmuir Blodgett film, functionalized glass, Si, Ge, GaAs, GaP, Si02, SiN4, modified silicon, or any one of a wide variety of polymers such as (poly)tetrafluoroethylene, (poly)vinylidenedifluoride, or combinations thereof. Other substrate materials will be readily apparent to those of skill in the art upon review of this disclosure. In a preferred embodiment the substrate is flat glass or single-crystal silicon with surface features of less than 10 angstroms.
Surfaces on the solid substrate will usually, though not always, be composed of the same material as the substrate. Thus, the surface may be composed of any of a wide variety of materials, for example, polymers, plastics, resins, polysaccharides, silica or silica-based materials, carbon, metals, inorganic glasses, membranes, etc., provided only that caged thiols can be attached to the surface of the substrate. Preferably, the surface will contain reactive groups, which could be carboxyl, amino, hydroxyl, or the like. Most preferably, the surface will be optically transparent and will have surface Si-OH functionalities, such as are found on silica surfaces.
The surface of the substrate is preferably provided with a layer of crosslinking groups, although one of ordinary skill will understand that the crosslinking groups are not required elements of the invention. The crosslinking groups are preferably of sufficient length to permit thiol groups on the surface, as well as biological polymers covalently attached to the thiol groups, to interact freely with compounds in solution. Crosslinking groups can be selected from any suitable class of compounds, for example, aryl acetylenes, ethylene glycol oligomers containing two to ten monomer units, dia ines, diacids, amino acids, or combinations thereof. Other crosslinking groups may be used in view of this disclosure. Crosslinking groups can be attached to the surface by a variety of methods that are readily apparent to one having skill in the art. For example, crosslinking groups may be attached to the surface by siloxane bonds formed via reactions of crosslinking groups bearing trichlorosilyl or trisalkoxy groups with hydroxyl groups on the surface of the substrate.
Preferably, the crosslinking group used with a glass surface is t-BOC-aminopropyltriethoxysilane. The crosslinking groups can optionally be attached in an ordered array, i.e., as parts of the head groups in a polymerized Langmuir Blodgett film. Clearly, the type of crosslinking group selected, and the method selected for attaching the crosslinking group to the surface, will depend primarily on the crosslinking group having
suitable reactivity with the compound carrying the thiol group desired to be attached to the surface.
Additional length may be added to the crosslinking groups by the addition of single or multiple linking groups. Such linking groups are preferably heterobifunctional, having one end adapted to react with the crosslinking groups and the other end adapted to react with the compound carrying the thiol group or another linking group. The linking groups may be attached by a variety of methods that are readily apparent to one skilled in the art, for instance, by esterification or amidation reactions of an activated ester of the linking group with a reactive hydroxyl or amine on the free end of the crosslinking group. A preferred linking group is N-BOC-6- aminocaproic acid (or N-BOC-6-aminohexanoic acid) attached by the BOP-activated ester. After deprotection to liberate the free amine terminus, another N-BOC-aminocaproic linker can be added. Attachment of crosslinking and linking groups to caged thiol compounds are discussed more fully below.
Many methods are available for immobilizing the compound carrying the thiol group of the present invention on surfaces. The compound carrying the thiol group can be linked to the surface and later provided with protecting (caging) groups. More preferably, compounds carrying the thiol group will be attached to the surface in a protected form. The method chosen for linking the compound carrying the thiol group to the surface will depend upon the chemical properties of the compound carrying the thiol group selected for attachment to the surface. A preferred method for immobilizing the compound carrying the thiol group of the present invention involves chemical derivatization or activation of the caged compound carrying the thiol group prior to attachment to the surface or linker.
This derivative or activated species is then reacted with functionalities on the substrate to give the desired linkage. For example, one method for attaching a compound carrying the thiol -group to a surface employs a bifunctional crosslinking reagent, such as diepoxide, which both activates the surface and provides a group that reacts with an activated
compound carrying the thiol group. Alternatively, some surfaces can be activated with cyanogen bromide. Likewise, in the presence of a carbodiimide or other activating agent, for example, an amine group on the surface can be coupled to a carboxyl group of a compound carrying the thiol group to effect the immobilization.
In one embodiment, the compound carrying the thiol group is a caged cysteine, or other thiol-containing synthetic or natural amino acid. Such compounds are useful in a wide variety of applications; for instance, one could carry out amino acid addition on either the amino or carboxyl groups of the protected cysteine and then, after photoactivation, derivatize the side chain of the cysteine residue. Such techniques will often employ different classes of protecting groups, so that one can modify the immobilized molecules at different reactive groups. These techniques include cyclization, where the cyclization step is controlled by the use of protecting groups on the two amino acid residues undergoing cyclization that are different from the protecting groups on amino acid residues that are not to be cyclized. See U.S. patent application Serial Nos. 796,727, filed November 22, 1991, and 946,239, filed September 16, 1992, each of which is incorporated herein by reference.
Many different protecting (caging) groups can be employed for modifying thiol groups to give the caged thiols of the present invention. The protecting groups should be sterically large enough to reduce the reactivity of the caged thiol with other substances to permit operability of the invention, although protecting groups utilizing other types of interactions, such as electronic, hydrophobic, etc., could be used. The selection of suitable caging groups will depend upon the size and chemical nature of the compound carrying the thiol group chosen and will- be readily apparent to one skilled in the art. The caging groups are photoactivatable. The properties and uses of photoreactive caged compounds have been reviewed. See McCray et al. , 1989, Ann. Rev. Biophvs. Biophys. Chem. .18.:239-270, which is incorporated herein by reference.
Preferably, the photosensitive cages will be activatable by low energy ultraviolet or visible light. Many, although not all, of the photosensitive protecting groups are aromatic compounds. Suitable photoremovable protecting groups are also described in, for example, Patchornik, 1970, J. Am- Chem. Soc. 92:6333. and Amit et al. , 1974, J. Orq. Chem. 3_9_:192, which are incorporated herein by reference. See also, Calbiochem Catalog (San Diego, CA, 1989), pp. 244-247, incorporated herein by reference. More preferably, the photosensitive protecting group will be a nitro benzylic compound, such as o-nitrobenzyl or benzylsulfonyl groups. In a preferred embodiment, 6- nitroveratryloxycarbonyl (NVOC) ; 6-nitropiperonyloxycarbonyl (NPOC) ; alpha, alpha-dimethyldimethoxybenzyloxycarbonyl (DDZ) , methyl 6-nitroveratryloxycarbonyl (MenVOC) , methyl-6- nitropiperonyloxycarbonyl (MeNPOC) , or 1-pyrenylmethyl is employed.
Clearly, many photosensitive protecting groups are suitable for use in the present method. Some examples of acceptable photosensitive protecting groups are presented in Table l, below, together with their corresponding wavelengths for deprotection.
Table 1 Protecting Groups Group Deprotection Wavelength
6-nitroveratryloxycarbonyl (NVOC) UV (300-350 nm) dimethyldimethoxybenzyloxycarbonyl (DDZ) UV (280-300 nm) nitrobenzyloxycarbonyl (NBOC) UV (300-350 nm)
5-bromo-7-nitroindolinyl (BNI) UV (420 nm) O-hydroxy-alpha-methyl-cinnamoyl (HMC) UV (300-350 nm)
2-oxymethylene anthraquinone (OMA) UV (350 nm)
Once the surface is covered with a plurality of caged thiol groups, selected regions of the surface may be irradiated to provide free thiols on the surface. In a preferred embodiment, the radiation is UV, near IR, or visible light. The light source may be coherent or noncoherent. In some embodiments, the exposed area is less than about 1 cm2 or less
than about 1 mm2. In preferred embodiments the irradiated area will be composed of a pattern of smaller, discrete irradiated areas, each of which is less than about 10,000 μm2 or, more preferably, less than about 100 μm2. Preferably, each individual synthesis site in the pattern is about 50 to 500
/--M2. Spaces between activated regions are not optional and, if used, will generally be greater than about 1 μm. Exposure of the surface to light will typically be carried out with a suitable mask using photolithographic techniques well known in the semiconductor industry and described in, for example, Sze, VLSI Technology. McGraw-Hill (1983) , which is incorporated herein by reference. See U.S. Patent No. 5,143,854.
In one embodiment, the mask is a transparent support material coated with a layer of opaque material (i.e., chrome- plated glass) . Portions of the opaque material are removed (or never deposited) , leaving a pattern that matches the precise pattern desired on the substrate surface. Alternatively the mask can be a sheet or film composed of a non-transparent substance (i.e., anodized aluminum) ,- which sheet or film has been perforated in the desired pattern. The mask is brought into close proximity with or directly into contact with the surface. Openings -in the mask correspond to locations on the surface where one desires to photoremove protecting groups from thiol groups. Alignment may be performed using conventional alignment techniques in which alignment marks are used to overlay accurately successive masks with previous patterning steps. Other alignment techniques may be used, for example, interferometric techniques such as the one described in Flanders et al. , 1977, App. Phys. Lett. 3_l:426-428, which is incorporated herein by reference.
To enhance contrast of light applied to the substrate, one may place contrast enhancement materials between the mask and the substrate. This contrast enhancement layer may comprise a molecule, such as -quinone diazide, which is decomposed by light. The light may be from a conventional incandescent source, an arc lamp, a laser, or the like. If noncoherent sources of light are used, one may utilize a thick or multi-layered mask to prevent spreading of the light on the
substrate. Generally, lasers may be preferable, because lasers can more easily provide wavelengths particularly suited for a chromophore of the photosensitive group.
While the invention is illustrated primarily herein by way of the use of a light source and mask to illuminate the substrate, other techniques may also be used. For example, the substrate may be rotated or oriented under a modulated laser or diode light source. Such techniques are discussed in, for example, U.S. Patent No. 4,719,615, which is incorporated herein by reference. The substrate may be irradiated either in contact with or not in contact with a solution but usually is irradiated in contact with a solution.
The solution may contain reagents to prevent byproducts of irradiation from interfering with subsequent binding reactions. Such byproducts might include, for example, carbon dioxide, nitrosocarbonyl compounds, styrene derivatives, indole derivatives, and products of the photochemical reactions of such compounds. Reagents added to the solution may include, for example, acidic or basic buffers, thiols, substituted hydrazines and hydroxylamines, reducing agents (e.g., NADH,
DTT, or bisulfite ion) , or reagents known to react with a given functional group (e.g., aryl nitroso plus glyoxylic acid aryl form hydroxamate plus C02) . Preferably, however, protecting groups will be selected that do not cause significant interference with the binding reactions. Also, wash steps can be incorporated so that the byproducts do not interfere with the reactions.
Once localization of the anti-ligand is complete, the light pattern can be changed and the same or a different anti- ligand, ligand, polymer, or monomer can be localized at other discrete sites on the- surface. Anti-ligands that are nucleic acids are especially preferred. In a preferred embodiment, a plurality of nucleic acid anti-ligands are immobilized on a surface by first attaching photoreactive caged thiols to the surface. The caged thiols on a predefined region of the surface are exposed to light to give reactive thiol groups. The reactive thiol groups on the predefined region are then incubated with a first activated nucleic acid anti-ligand to be
immobilized, the surface is washed free of unreacted nucleic acid, and the surface is incubated with a desired ligand. The exact incubation conditions, e.g., time, temperature, pH, etc., will depend upon the species used and will be readily apparent to one skilled in the art. After washing the surface free of unbound nucleic acid, the above steps can be repeated on a different region of the surface with a different nucleic acid. In this fashion, a small, dense array of-, e.g., oligonucleotide probes, can be prepared. A surface prepared according to the methods described above can be used to screen for ligands having high affinity for immobilized anti-ligands. Screening can be performed by immobilizing a plurality of anti-ligands on predefined regions of a surface by the methods described above. A solution containing a marked (labelled) ligand is introduced'to the surface and incubated for a suitable period of time. The surface is then washed free of unbound ligand, and the anti- ligands having high affinity for the ligand are identified by identifying those regions on the surface where markers are located. Suitable markers include, but are not limited to, radiolabels, chromophores, fluorophores, chemiluminescent moieties, and transition metals. When autoradiography is the detection method used, the marker is a radioactive label, such as 32P. The marker on the surface is exposed to X-ray film, which is developed and read out on a scanner. An exposure time in the range of 1 to 24 hours is typical. Fluorescence detection using a fluorophore label, such as fluorescein, attached to the ligand will usually require much shorter exposure times. Alternatively, the presence of ligands may be detected using a variety of other techniques, such as an assay with a labelled enzyme, antibody, or the like. Other techniques using various marker systems for detecting bound ligand will be readily apparent to those skilled in the art. See U.S. Patent No. 5,143,854. In a preferred embodiment, a substrate prepared as discussed above can be exposed to a solution containing one or more ligands such as nucleic acids. The ligand can be labeled in any of a variety of ways, but in one embodiment, the ligand
is an oligonucleotide probe having a radioactive (or other) label. The ligand nucleic acid binds (hybridizes) with high affinity to an immobilized nucleic acid previously localized on the surface and to the complementary labeled probe. Hybridization conditions are known in the art, but the arrays of the invention allow one to use very small volumes of target- containing solution for analysis. In fact, by using micropipettes to deliver very small volumes (i.e., 1 to 5 μL or less) very precisely, one can allow evaporation to drive hybridization. After washing the surface free of nonspecifically bound ligand and labeled probe, the surface is placed proximate to X-ray film, if a radioactive label is employed, to identify the nucleic acids on the surface complementary to the nucleic acid ligand. Alternatively, a fluorescent label can be used, and detection can be accomplished with a charge-coupled device (CCD) , fluorescence microscopy, or laser scanning. A related labeling technique involves the use of a labeled probe in solution that will hybridize with the target nucleic acid ligand without interferring with hybridization of the ligand to the immobilized probe.
In another embodiment useful for performing many parallel hybridization reactions in solution in a single reaction vessel using an immobilized array of probes, one uses a set of capture probes in solution. The capture probes are designed to have a sequence complementary to the target sequence to be detected and a sequence complementary to an immobilized probe located at one or more discrete locations on the surface of the substrate. In this system, either the capture probe is labeled or another labeled probe complementary to the target sequence to be detected is employed. This system allows the hybridization of probe to target sequence to be carried out in solution, because the immobilized probe array does not have to be (but can be, if desired) present in the reaction mixture during hybridization of the capture probe to the target sequence. This system also allows one to design the capture sequence, the complementary sequence of nucleotides in the immobilized probe and the capture probe, without constraint
from the target sequence. These advantages allow one to perform an assay for many different target nucleic acids simultaneously and yet still identify whether any particular target nucleic acid is present in the sample tested. Quantitative assays for ligand concentrations can also be performed according to the present invention. In a direct assay method, the surface containing localized anti- ligands prepared as described above is incubated with a solution containing a labeled ligand for a suitable period of time. The surface is then washed free of unbound ligand. The amount of label present at predefined regions of the surface is then measured and can be related to the amount of ligand in solution. Methods and conditions for performing such assays are well-known and are presented in, for example, Hood et al., Immunology (Benjamin/Cummings 1978) and Harlow et al..
Antibodies: A Laboratory Manual (Cold Spring Harbor Laboratory 1988) , each of which is incorporated herein by reference. See also U.S. Patent No. 4,376,110, incorporated herein by reference, for methods of performing sandwich assays. The precise conditions for performing these steps will be apparent to one skilled in the art.
A competitive assay method can also be employed using the methods and reagents of the present invention. Such a method involves immobilizing anti-ligands on predefined regions of a surface as described above. An unmarked ligand is then bound to anti-ligands on the surface having specific binding affinity for the ligand. A solution containing marked ligand is then introduced to the surface and incubated for a suitable time. The surface is then washed free of unbound reagents, and the amount of marker remaining on the surface is measured.
Alternatively, marked and unmarked ligand can be exposed to the surface simultaneously. The amount of marker remaining on predefined regions of the surface can be related to the amount of unknown ligand in solution. The invention is illustrated in the Examples below primarily with reference to the identification of specific nucleic acid sequences in a sample. The invention will, however, find many other uses. For example, the invention can
be used in information storage (e.g., on optical disks), production of molecular electronic devices, production of stationary phases in separation sciences, and in immobilization of- cells, proteins, lectins, nucleic acids, polysaccharides and the like in any desired pattern on a surface via molecular recognition of a specific anti-ligand linked via a thiol group to a surface of a substrate.
The above description is intended to be illustrative and not restrictive. Many embodiments will be apparent to those of skill in the art upon reviewing the above description. The scope of the invention should, therefore, be determined not with reference to the above description or the following Examples, but should instead be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.
Example 1 Preparation of Substrate and Thiol-derivatized Surface A. Preparation of Substrate Surface Commercially available glass microscope slides (for example, 1" x 3" smooth cut, 0.7 mm thick, anti-scratch coated slides or 2" x 3" smooth cut, 0.7 -mm thick, anti-scratch coated slides from Erie Scientific) were derivatized with t-BOC- aminopropyltriethoxy silane in substantial accordance with the procedure described in J. Chromatography 97:33 (1974), incorporated herein by reference.
Thus, the slides were cleaned by soaking in 10% Micro detergent (Baxter) , individually scrubbed, and immersed in deionized water. The slides were then subjected to a 10 minute sonication in a 70°C solution of 10% Micro detergent and rinsed ten times with deionized water. This process was followed by a three minute immersion in a 70°C solution of 10% (w/v) NaOH. The slides were then rinsed ten times with deionized water, and then immersed for one minute in 1% HC1. The slides were then again rinsed ten times with deionized water, and then subjected to another 10 minute sonication in 70°C deionized water, after which the slides were rinsed three to four times in deionized water. The slides were then ethanol rinsed and dried with
nitrogen or argon. The slides were then inspected visually for spots and scratches in a yellow light with a black background, and any slides that were scratched- or spotted or that still retained the anti-scratch coating were either discarded or recleaned.
An alternate or additional cleaning procedure is carried out as follows. The slides are loaded into teflon racks and subjected to a thirty minute immersion in a solution composed of Nochromix (Aldrich) with 36 g/L of concentrated sulfuric acid (which can be regenerated if discolored) that has been filtered (glass fiber filter) to remove particulate matter. Occasional agitation is provided during the thirty minute immersion step. The slides are then rinsed for one minute in deionized water with vigorous agitation. The slides are then placed for ten minutes in a rinse tank with 14 psi argon or nitrogen bubbling, a full open deionized water tap, and occasional agitation.
The slides are then immersed for three minutes in a 70°C solution of 10% (w/v) NaOH, followed by a one minute rinse with deionized water and vigorous agitation, followed by a ten minute rinse in a rinse tank. The slides are then immersed for one minute in 1% HC1 and then rinsed for five minutes in a rinse tank. The slides are then ethanol rinsed, dried with nitrogen or argon, and inspected visually for spots and scratches.
The t-BOC aminopropyl derivatization is carried out as follows. The slides are loaded into plastic staining jars, with about nine slides per jar. Preferably, the slides are completely dry when placed in the staining jars, and the silation reagents are added as follows. The silation reagent is a premixed solution of a 1:10 molar ratio of t-BOC- aminopropyltriethoxysilane:methyltriethoxysilane (i.e., 1 L of t-BOC-aminopropyltriethoxysilane and 5.86 mL of methyltriethoxysilane, which is kept anhydrous and stored under argon) . The silation reagent is diluted to 1% (v/v) in dichloromethane (DCM) , mixed well, and 60 mL of the diluted silation reagent are added to each jar. The jars are capped and incubated overnight at room temperature. Then, the slides
are removed from the jar, rinsed first with DCM and then with toluene and then dried immediately with argon. The slides are then loaded onto glass drying racks, inspected for streaks, and allowed to stand for approximately thirty minutes. The slides are then baked for one hour in a 100°C oven with the glass racks in metal trays covered with foil. The oven should be no hotter than 110°C. The slides are then cooled and optionally numbered with an engraving tool.
The slides, prepared as described above, were then incubated at room temperature in a solution of 50% trifluoroacetic acid/50% DCM for forty minutes to remove the t- BOC protecting group. After being washed sequentially with DCM and then twice with a solution of 5% diisopropylethylamine (DIEA) in methylene chloride for 5- minutes each wash, the slides were then washed with methylene chloride, then with ethanol, and then the slides were dried with argon. The slides were derivatized within one hour of drying.
B. Preparation of Nitroveratrylthiolpropionic Acid Nitroveratrylthiolpropionic acid was prepared in substantial accordance with the protocols set forth in Patchornik et al.. , 21 Oct. 1970, J. Am« Chem. Soc. 92(21) :6333- 6335, incorporated herein by reference.
About 500 mg (0.0018 moles) of bromonitroveratryl (NVBr) were added to a solution containing 160 μL (0.0018 moles) of thiolpropionic acid (HSCH2CH2C02H) , 6 mL of dimethylformamide (DMF) , and 364 mg (0.0036 moles) of triethylamine (Et3N) . After about five minutes, a precipitate -(Et3N+HBr) formed, and the reaction was deemed complete after analysis with thin layer chromatography (TLC in 10% methanol/dichloromethane) . The reaction mixture was then diluted with 100 mL of methylene chloride and washed with 50 mL of 1 N- NaOH. The aqueous phase was separated, acidified with 1 N HC1, extracted with methylene chloride, and then the organic layer was dried (Na2S04) , and ihen rotary evaporated to dryness. About 0.54 g of nitroveratrylthiolpropionic acid was obtained. The product can be further purified by dissolving
the product in ethanol, adding five volumes of water, and collecting the needle-shaped crystals by filtration.
C. Coupling of Nitroveratrylthiolpropionic Acid to Substrate Surface
A solution composed of 60 mg of nitroveratrylthiolpropionic acid, 70 μL of DIEA, 29.8 mg of HOBT (1-hydroxybenzotriazole hydrate), and 0.2 mL of DMF was mixed at room temperature for 10 minutes with a solution composed of 88.5 mg of BOP (benzotriazol-1-yloxytris-
(dimethylamino) phosphonium hexafluorophosphate) and 0.2 L of DMF. The resulting mixture was then diluted with 1.6 mL of DMF,- and about 0.5 mL of the resulting mixture was applied to each 1" x 3" slide. The slides were then immersed with a 3:1 (v/v) solution of pyridin :acetic anhydride with 0.1% DMAP (4- dimethylaminopyridine) . The resulting slides were then used in the coupling and hybridization experiments described below.
Example 2 Coupling of Fluorescein Maleimide to Substrate Surface A glass microscope slide- prepared as described in Example IC was mounted on a flow cell and illuminated through a 500 μm 500 μm checkerboard-pattern mask (Photo Sciences Inc. , Torrance, CA) using broad-band UV/blue light. This pattern was repeated in triplicate on each slide, and the illumination was carried out so that one region underwent a four minute photolysis, a second region underwent a two minute hydrolysis, and a third region underwent a one minute photolysis. The light source was a 500 W Mercury arc lamp (Oriel Model 87330) equipped with a 350 nm - 450 nm dichroic reflector that produced actinic light having an intensity of 12 mW/cm2 as measured through a 360 nm bandpass filter. The derivatized surface was photolyzed in flowing dioxane for 15 minutes and then rinsed in ethanol and dried with argon. About 4.3 mg of fluorescein maleimide (Molecular
Probe) were dissolved in 10 mL of warm DMF to obtain a one mM solution of fluorescein maleimide. This solution was allowed to cool to room temperature, and then the slide was immersed in
the solution and incubated at room temperature for two hours with gentle agitation. The slide was then removed from the solution and rinsed sequentially with DMF, ethanol, methylene chloride, and again with ethanol, and then the slide was dried with argon.
The slide was examined with a scanning fluorescence microscope (Zeiss Axioskop equipped with a Newport Model PM500- C motion controller, a Spectra-Physics Model 2020 argon-ion laser producing a 488 nm excitation light; and a 520 nm long- pass emission filter) interfaced with a photon-counting device (Hamamatsu Model 9403-02 photomultiplier; Stanford Research Systems Model SR445 amplifier and Model SR430 multichannel sealer, IBM compatible PC) to generate a two-dimensional image consisting of fluorescence intensity data as a function of x,y position. The results of this analysis revealed the pattern of illuminated and dark squares expected from the fluorescein maleimide coupling to the deprotected thiol groups in the illuminated squares. This experiment demonstrates that the photochemically protected thiols are competent for coupling to a maleimide-containing compound after photodeprotection.
Example 3 Coupling of Oligonucleotides with Thiol-reactive Groups to Substrate Surface This example shows the results of a test for the effectiveness of several different thiol-reactive groups that, when attached to an oligonucleotide, enable covalent coupling to thiol-derivatized glass slides.
A 5*-fluoresceinated 3'-C6-amino oligonucleotide probe (designated CAP2, which was prepared using the Clonetech reagent 3*-C6-amino-modifier-CPG) was activated with the following heterobifunctional reagents: (1) succinimidyl bromoacetate (BrAc-NHS) ; (2) succinimidyl iodoacetate (IAc- NHS) ; (3) succinimidyl 6-( (iodoacetyl)amino)hexanoate (SIAX) ; (4) succinimidyl 6-(6-(( (iodoacetyl)amino)hexanoyl)amino)- hexanoate (SIAXX) ; and (5) succinimidyl 6-maleimidylhexanoate (EMCS) . The activation reactions were carried out in separate reaction mixtures containing: 0.2 mM oligonucleotide; 0.25 M
Na borate, pH = 8.3; 40 nK of one of the five NHS esters listed above; 24% acetonitrile; and 24% DMF, typically in a total volume of 200 μL. The reaction was incubated at 25°C for 30 minutes, and the resulting modified oligonucleotide was desalted on a G-25 spin column (unbuffered water) and then used without further purification at a concentration of about 100 μM (determined spectrophotometrically) . Polyacrylamide gel electrophoresis assays after quenching- with a fluorescent thiol indicated that about 75% of the oligonucleotides were modified in the.reaction.
The modified oligonucleotides were applied at a concentration of about 100 μM in unbuffered water to a freshly photolyzed thiol-containing slide prepared as described in Example 1. About 5 μL of each oligonucleotide were applied to each well on the slide. The wells were created on the slide using a twelve well template with O-rings to seal the template to the slide. After each oligonucleotide was added to a well, about 5 μL of a buffer solution composed of 100 mM HEPES, pH = 8.0, 5 mM EDTA, and 5 mM DTAB (dodecyl trimethyl ammonium bromide) were added to each well to initiate the reaction. The reaction mixtures were incubated at room temperature for four hours in the dark, and then the wells were rinsed with water and the slide was removed and washed in a solution composed of 2%- SDS in Tris-buffer at pH = 8 at 65°C overnight. The slides were then washed with water and ethanol, then dried. Surface fluorescence on the- slide was then imaged using a scanning 488 nm laser induced fluorescence microscope. Average fluorescence intensities per pixel in the immobilization sites were used as a measure of oligonucleotide binding (covalent coupling to surface thiols) .
The results of the scanning are presented graphically in Pig. 1. The results show that none of the haloacetyl activating groups enhanced binding significantly above the background non-specific binding but that the maleimide activating group (EMCS) enhanced binding five-fold over background non-specific binding. These results do not indicate that the other activating groups tested (including cyanuric chloride, tested in a separate experiment) are unsuitable for
coupling to the substrates of the invention but instead indicate that of the activating groups tested, the maleimide activating group is preferred under the conditions employed.
Example 4
Coupling Efficiency of Maleimide-activated Oligonucleotides to Substrate Surface — Effect of Various Additives
This example shows the results of the addition of a variety of additives on the coupling efficiency of a maleimide- activated, 5'-fluoresceinated oligonucleotide to thiol- derivatized slides. In this example, the 5*-fluoresceinated 3'—C6-amino oligonucleotide was activated with succinimidyl 6- maleimidylhexanoate and applied to a freshly photolyzed slide as a solution in water in substantial accordance with the procedure set forth in Example 3.
Each different additive was added to the coupling initiation buffer (100 mM HEPES, pH = 8.0, 5 mM EDTA, and the additive) . After the coupling reaction, the slides were washed and scanned as described in Example 3. The results of the scanning are presented graphically in Fig. 2. The results show that the anionic, zwitterionic, and neutral detergents did not appear to enhance coupling efficiency; the salts TMAC (trimethylammonium chloride) and LiCl gave a moderate enhancement in coupling efficiency; and the cationic detergent DTAB caused a large enhancement in coupling efficiency at relatively low concentrations (2.5 mM; at higher concentrations, greater than 10 mM, the oligonucleotide precipitated) . Other additives of interest include compounds such as spermidine, spermine, polyamines, polyethyleneimine, and other cationic detergents similar to DTAB, and other salts similar to LiCl.
Example 5 Hybridization of Nucleic Acids to Immobilized Oligonucleotide Two glass slides prepared in accordance with the procedures set forth in Examples 3 and 4 were tested for ability to hybridize specifically with a complementary oligonucleotide. The two slides differed with respect to the
additive present during the coupling reaction; one slide was coupled to oligonucleotide in the presence of LiCl, the other in the presence of DTAB.
The slides were prehybridized individually in heat sealed bags at 56°C with a solution composed of 6X SSC, 6X Denhardt's solution, 0.5% SDS, and 100 μg/mL of sheared, denatured, salmon sperm DNA. The hybridization reaction was carried out at 53.5°C (TM minus 5°C) in prehybridization buffer containing 1 pmole of a 32P-end labeled 60mer probe (specific activity of 1.5 x 108 CPM/μg) containing a 30 nucleotide segment perfectly complementary to the covalently coupled oligonucleotide probe. The hybridized slides were evaluated in a beta plate counter and by autoradiography.
The results showed that the labeled probe hybridized specifically to the covalently coupled oligonucleotide with very little background.
Example 6
Rehvbridization of Nucleic Acids to Oligonucleotide-derivatized Substrate Surface
The slides hybridized to labeled probe in accordance with the procedure of Example 5 were washed three times with a
100°C solution of 0.01% SDS. The slides were then allowed to expose XAR film overnight at -70°C to determine whether the labeled probe had been removed. The results showed complete removal of the probe from all but two sites, which showed only weak signal.
Rehybridization with the labeled probe of Example 5 was carried out using the Stratagene Qwik-Hyb™ hybridization accelerator solution following the package insert directions.
Other hybridization acceleration reagents that can be employed in the method of the present invention include Al protein, RecA protein, SSB, dextran sulfate, ficoll, phenol, and detergent.
Prehybridization was carried out for 15 minutes at 53.5°C, and then 100 μL of 10 mg/mL salmon sperm DNA was added to the slides together with 10 μL (one pmole) of the labeled probe.
The hybridization reaction was carried out at 53.5°C for one
hour. The slides were washed and then allowed to expose XAR film overnight at -70°c.
The results showed that the slides to which oligonucleotide had been coupled in LiCl gave an even stronger signal than after the first hybridization and that the slides to which oligonucleotide had been coupled in DTAB gave a weaker but still clear signal than after the first hybridization. Both slides showed very little background signal.
Example 7
Specific Hybridization of Nucleic Acids to Immobilized Oligonucleotide Probe Array A slide prepared as described in Example 1 is photolyzed under dioxane and then rinsed with ethanol and dried under a nitrogen stream. The slide is clamped to a template that forms a well over the photolyzed area, and 20 μL of a 100 μM solution of 3•-EMCS-activated probe CAP2 (δ'-CCAACTCTTTTTCCGAAGGTAACTGGCTTC [SEQ. ID NO. 1]) in unbuffered water and HEPES/EDTA/DTAB buffer are added to the well. The slide and template are then incubated at room temperature for two hours, the reaction is quenched by the addition of N-ethyl maleimide, and the slide is rinsed liberally first with water and then with dioxane. The slide is then re-photolyzed to activate a different region on the slide and then coupled to 3'-ECMS-activated probe CAP5 (51-
GTTCCGCAGGTTCTCTCG- GTCAGTCTGTGC [SEQ. ID NO.2]). After the coupling reaction is quenched as before, the slide is rinsed with water and then washed for 12 hours in a 65°C solution of 2% SDS. The slide is then hybridized to a first labeled target nucleic acid complementary to probe CAP2, and the specificity of hybridization is determined. The slide is then washed to remove the labeled target nucleic acid, and a second labeled target nucleic acid complementary to probe CAP5 is added, and the specificity of hybridization is determined. The results demonstrate that the methods and reagents of the invention provide a very sensitive and specific assay for target nucleic acid sequences.
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: McGall, Glenn H.
Fodor, Stephen P. . Sheldon, Edward L.
(ii) TITLE OF INVENTION: Spatially-Addressable Immobilization of
Oligonucleotides and Other Biological Polymers on Surfaces
(iii) NUMBER OF SEQUENCES: 2
(ΪV) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: William M. Smith
(B) STREET: One Market Plaza, Steuart Tower, Suite 2000
(C) CITY: San Farancisco
(D) STATE: California
(E) COUNTRY: USA CF) ZIP: 94105
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: Patentln Release #1.0, Version #1.25
(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: US
(B) FILING DATE: 04/24/92
(C) CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Smith, William M.
(B) REGISTRATION NUMBER: 30,223
(C) REFERENCE/DOCKET NUMBER: 11509-41
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 415-543-9600
(B) TELEFAX: 415-543-5043
(2) INFORMATION FOR SEQ ID NOM:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi> SEQUENCE DESCRIPTION: SEQ ID NO:l: CCAACTCTTT TTCCGAAGGT AACTGGCTTC 30
SUBSTITUTE SHEET
29
(2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: GTTCCGCAGG TTCTCTCGGT CAGTCTGTGC
SUBSTITUTE SHEET
Claims
1. A method for forming predefined regions on a surface of a solid support, the -predefined regions capable of selectively immobilizing a biological polymer, the method comprising: a) attaching to the surface a compound carrying a thiol group, which thiol group is covalently coupled to a photochemically removable protecting group; and b) selectively irradiating the predefined regions of the surface to remove said photochemically removable protecting group from said thiol group in the predefined regions.
2. The method of claim 1, wherein said solid support is selected from the group consisting of polymerized Langmuir Blodgett film, functionalized glass. Si, Ge, GaAs, GaP, Si02, SiN4, modified silicon, (poly)tetrafluoroethylene, and (poly)vinylidenedifluoride solid supports.
3. The method of claim 1, wherein said photochemically removable protecting group is selected from the group consisting of 6-nitroveratryloxycarbonyl, dimethyldimethoxybenzyloxycarbonyl, nitrobenzyloxycarbonyl, 5-bromo-7-nitroindolinyl, O-hydroxy-alpha-methyl-cinnamoyl, methyl 6-nitroveratryloxycarbonyl, methyl-6- nitropiperonyloxycarbonyl, and 2-oxymethylene anthraquinone.
4. The method of claim 1, wherein said solid support is a functionalized glass slide and said photochemically removable protecting group is 6-ntroveratryloxycarbonyl.
5. The method of claim 4, wherein said functionalized glass slide has been functionalized by treatment with t-BOC- aminopropyltriethoxysilane.
6. The method of claim 4, wherein said compound carrying a thiol group is nitroveratrylthiolpropionate.
7. The method of claim 4, which method further comprises coupling an activated oligonucleotide to said thiol group in said predefined regions.
8. The method of claim 7, wherein said functionalized glass slide has been functionalized by treatment with N-BOC- aminopropyltriethoxysilane and said --:ompound carrying a thiol group is nitroveratrylthiolpropionate.
9. The method of claim 7, wherein said activated oligonucleotide has been activated with succinimidyl 6-maleimidylhexanoate.
10. The method of claim 8, wherein said coupling step is carried out in the presence of a cationic detergent.
11. The method of claim 10, wherein said cationic detergent is DTAB.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/874,849 | 1992-04-24 | ||
US07/874,849 US5412087A (en) | 1992-04-24 | 1992-04-24 | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993022680A1 true WO1993022680A1 (en) | 1993-11-11 |
Family
ID=25364706
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1993/003767 WO1993022680A1 (en) | 1992-04-24 | 1993-04-21 | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces |
Country Status (3)
Country | Link |
---|---|
US (1) | US5412087A (en) |
AU (1) | AU4110793A (en) |
WO (1) | WO1993022680A1 (en) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995021265A1 (en) * | 1994-02-01 | 1995-08-10 | Isis Innovation Limited | Methods for discovering ligands |
US5604097A (en) * | 1994-10-13 | 1997-02-18 | Spectragen, Inc. | Methods for sorting polynucleotides using oligonucleotide tags |
EP0764214A1 (en) * | 1994-06-08 | 1997-03-26 | Affymax Technologies N.V. | Bioarray chip reaction apparatus and its manufacture |
EP0804731A1 (en) * | 1994-06-17 | 1997-11-05 | The Board Of Trustees Of The Leland Stanford Junior University | Method and apparatus for fabricating microarrays of biological samples |
US5695934A (en) * | 1994-10-13 | 1997-12-09 | Lynx Therapeutics, Inc. | Massively parallel sequencing of sorted polynucleotides |
US5858666A (en) * | 1996-08-29 | 1999-01-12 | Biotechnology Research And Development Corporation | Apparatus and method of detection employing an AC frequency sensor array |
EP0920440A2 (en) * | 1996-02-09 | 1999-06-09 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
DE19853640A1 (en) * | 1998-11-20 | 2000-06-08 | Molecular Machines & Ind Gmbh | Multi-vessel arrangement with improved sensitivity for optical analysis |
US6138077A (en) * | 1994-10-13 | 2000-10-24 | Lynx Therapeutics, Inc. | Method, apparatus and computer program product for determining a set of non-hybridizing oligonucleotides |
WO2001001142A2 (en) * | 1999-06-29 | 2001-01-04 | Chiron Corporation | Arrays of biopolymeric agents and method for their production and use |
US6280935B1 (en) | 1994-10-13 | 2001-08-28 | Lynx Therapeutics, Inc. | Method of detecting the presence or absence of a plurality of target sequences using oligonucleotide tags |
US6576752B1 (en) | 1997-02-14 | 2003-06-10 | Isis Pharmaceuticals, Inc. | Aminooxy functionalized oligomers |
EP1421201A2 (en) * | 2001-07-31 | 2004-05-26 | New York Institute Of Technology | Methods for immobilizing molecules to a solid phase and uses thereof |
DE10260431A1 (en) * | 2002-12-21 | 2004-07-01 | Forschungszentrum Jülich GmbH | Self-justifying immobilization of living cells on a silicon substrate, useful in preparation of sensors, by attaching mutually interacting molecules to surfaces of cells and substrate |
US6852487B1 (en) | 1996-02-09 | 2005-02-08 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
US7097980B2 (en) | 1996-05-29 | 2006-08-29 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions |
US7138268B2 (en) | 1995-03-28 | 2006-11-21 | Agilent Technologies, Inc. | Dry biochemical assay plate and method for making the same |
US7195872B2 (en) | 2001-11-09 | 2007-03-27 | 3D Biosurfaces, Inc. | High surface area substrates for microarrays and methods to make same |
US7455965B2 (en) | 2000-04-14 | 2008-11-25 | Cornell Research Foundation, Inc. | Method of designing addressable array for detection of nucleic acid sequence differences using ligase detection reaction |
US7932213B2 (en) | 1999-05-11 | 2011-04-26 | President And Fellows Of Harvard College | Small molecule printing |
USRE43097E1 (en) | 1994-10-13 | 2012-01-10 | Illumina, Inc. | Massively parallel signature sequencing by ligation of encoded adaptors |
US8140148B2 (en) | 1998-01-20 | 2012-03-20 | Boston Scientific Scimed Ltd. | Readable probe array for in vivo use |
Families Citing this family (536)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744101A (en) * | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
US6955915B2 (en) * | 1989-06-07 | 2005-10-18 | Affymetrix, Inc. | Apparatus comprising polymers |
US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
US5547839A (en) * | 1989-06-07 | 1996-08-20 | Affymax Technologies N.V. | Sequencing of surface immobilized polymers utilizing microflourescence detection |
DE69132843T2 (en) | 1990-12-06 | 2002-09-12 | Affymetrix Inc N D Ges D Staat | Identification of nucleic acids in samples |
US5474796A (en) * | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
US6589726B1 (en) | 1991-09-04 | 2003-07-08 | Metrigen, Inc. | Method and apparatus for in situ synthesis on a solid support |
US6921636B1 (en) * | 1991-09-04 | 2005-07-26 | Metrigen, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
US5849486A (en) * | 1993-11-01 | 1998-12-15 | Nanogen, Inc. | Methods for hybridization analysis utilizing electrically controlled hybridization |
US6051380A (en) * | 1993-11-01 | 2000-04-18 | Nanogen, Inc. | Methods and procedures for molecular biological analysis and diagnostics |
US5677195A (en) * | 1991-11-22 | 1997-10-14 | Affymax Technologies N.V. | Combinatorial strategies for polymer synthesis |
US6943034B1 (en) * | 1991-11-22 | 2005-09-13 | Affymetrix, Inc. | Combinatorial strategies for polymer synthesis |
US5384261A (en) * | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
EP1382386A3 (en) * | 1992-02-19 | 2004-12-01 | The Public Health Research Institute Of The City Of New York, Inc. | Novel oligonucleotide arrays and their use for sorting, isolating, sequencing, and manipulating nucleic acids |
JPH0622798A (en) * | 1992-07-07 | 1994-02-01 | Hitachi Ltd | Method for determining base sequence |
US6436635B1 (en) * | 1992-11-06 | 2002-08-20 | Boston University | Solid phase sequencing of double-stranded nucleic acids |
US5795714A (en) * | 1992-11-06 | 1998-08-18 | Trustees Of Boston University | Method for replicating an array of nucleic acid probes |
EP0687307A4 (en) * | 1993-02-18 | 1997-11-26 | Univ Massachusetts Medical | Inhibition of tax-mediated increase in dna binding |
US6156501A (en) * | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
US7097839B1 (en) * | 1993-10-26 | 2006-08-29 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
US5879656A (en) * | 1993-10-26 | 1999-03-09 | Thomas Jefferson University | Methods of treating metastatic colorectal cancer with ST receptor binding compounds |
US7375198B2 (en) * | 1993-10-26 | 2008-05-20 | Affymetrix, Inc. | Modified nucleic acid probes |
US20030232361A1 (en) * | 1993-10-26 | 2003-12-18 | Affymetrix, Inc. | Nucleic acid array preparation using purified phosphoramidites |
US6045996A (en) * | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
US7378236B1 (en) * | 1994-06-17 | 2008-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method for analyzing gene expression patterns |
US7323298B1 (en) | 1994-06-17 | 2008-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Microarray for determining the relative abundances of polynuceotide sequences |
US6327031B1 (en) * | 1998-09-18 | 2001-12-04 | Burstein Technologies, Inc. | Apparatus and semi-reflective optical system for carrying out analysis of samples |
US8236493B2 (en) * | 1994-10-21 | 2012-08-07 | Affymetrix, Inc. | Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA |
US5585069A (en) * | 1994-11-10 | 1996-12-17 | David Sarnoff Research Center, Inc. | Partitioned microelectronic and fluidic device array for clinical diagnostics and chemical synthesis |
EP0791238B1 (en) * | 1994-11-10 | 2004-09-22 | Orchid BioSciences, Inc. | Liquid distribution system |
US5603351A (en) | 1995-06-07 | 1997-02-18 | David Sarnoff Research Center, Inc. | Method and system for inhibiting cross-contamination in fluids of combinatorial chemistry device |
US6475721B2 (en) * | 1995-03-04 | 2002-11-05 | Boston Probes, Inc. | Sequence specific detection of nucleic acids using a solid carrier bound with nucleic acid analog probes |
US7803529B1 (en) | 1995-04-11 | 2010-09-28 | Sequenom, Inc. | Solid phase sequencing of biopolymers |
US20060063193A1 (en) * | 1995-04-11 | 2006-03-23 | Dong-Jing Fu | Solid phase sequencing of double-stranded nucleic acids |
US5830539A (en) * | 1995-11-17 | 1998-11-03 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon | Methods for functionalizing and coating substrates and devices made according to the methods |
US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
US6300063B1 (en) | 1995-11-29 | 2001-10-09 | Affymetrix, Inc. | Polymorphism detection |
US6953663B1 (en) | 1995-11-29 | 2005-10-11 | Affymetrix, Inc. | Polymorphism detection |
US20110028350A1 (en) * | 1995-12-15 | 2011-02-03 | Affymetrix, Inc. | Photocleavable protecting groups |
US6147205A (en) * | 1995-12-15 | 2000-11-14 | Affymetrix, Inc. | Photocleavable protecting groups and methods for their use |
EP0880598A4 (en) | 1996-01-23 | 2005-02-23 | Affymetrix Inc | Nucleic acid analysis techniques |
US20020150921A1 (en) * | 1996-02-09 | 2002-10-17 | Francis Barany | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
US6063633A (en) | 1996-02-28 | 2000-05-16 | The University Of Houston | Catalyst testing process and apparatus |
US6458530B1 (en) | 1996-04-04 | 2002-10-01 | Affymetrix Inc. | Selecting tag nucleic acids |
US6251691B1 (en) | 1996-04-25 | 2001-06-26 | Bioarray Solutions, Llc | Light-controlled electrokinetic assembly of particles near surfaces |
US5872015A (en) * | 1996-05-10 | 1999-02-16 | Board Of Trustees Of The University Of Illinois | Molecular diversity screening method |
US5958342A (en) * | 1996-05-17 | 1999-09-28 | Incyte Pharmaceuticals, Inc. | Jet droplet device |
DE19621177A1 (en) | 1996-05-24 | 1997-11-27 | Basf Ag | Carbohydrate derivatives and their synthesis on solid phase |
US6103479A (en) * | 1996-05-30 | 2000-08-15 | Cellomics, Inc. | Miniaturized cell array methods and apparatus for cell-based screening |
US20060141539A1 (en) * | 1996-05-30 | 2006-06-29 | Taylor D L | Miniaturized cell array methods and apparatus for cell-based screening |
SE9602545L (en) * | 1996-06-25 | 1997-12-26 | Michael Mecklenburg | Method of discriminating complex biological samples |
US20050069923A1 (en) * | 1996-07-08 | 2005-03-31 | Mullis Kary Banks | Dual bead assays using cleavable spacers and/or ligation to improve specificity and sensitivity including related methods and apparatus |
NZ333907A (en) | 1996-07-08 | 2000-09-29 | Burstein Lab Inc | Cleavable optically detectable elements on substrate for microanalysis of chemical species |
US6342349B1 (en) | 1996-07-08 | 2002-01-29 | Burstein Technologies, Inc. | Optical disk-based assay devices and methods |
US20050214827A1 (en) * | 1996-07-08 | 2005-09-29 | Burstein Technologies, Inc. | Assay device and method |
US6331275B1 (en) | 1996-07-08 | 2001-12-18 | Burstein Technologies, Inc. | Spatially addressable, cleavable reflective signal elements, assay device and method |
US6391550B1 (en) * | 1996-09-19 | 2002-05-21 | Affymetrix, Inc. | Identification of molecular sequence signatures and methods involving the same |
US7094609B2 (en) * | 1996-09-20 | 2006-08-22 | Burstein Technologies, Inc. | Spatially addressable combinatorial chemical arrays in encoded optical disk format |
NZ335453A (en) | 1996-12-12 | 2001-07-27 | Prolume Ltd | Microelectronic device with microlocations including photodetector for detecting bioluminescence |
US5773308A (en) * | 1997-02-10 | 1998-06-30 | The United States Of America As Represented By The Secretary Of The Navy | Photoactivatable o-nitrobenzyl polyethylene glycol-silane for the production of patterned biomolecular arrays |
WO1998035707A1 (en) | 1997-02-18 | 1998-08-20 | Thomas Jefferson University | Compositions that bind to pancreatic cancer cells and methods of using the same |
PL335226A1 (en) | 1997-02-21 | 2000-04-10 | Burstein Lab | Gene sequencer and related methods |
US5837860A (en) * | 1997-03-05 | 1998-11-17 | Molecular Tool, Inc. | Covalent attachment of nucleic acid molecules onto solid-phases via disulfide bonds |
JP4313861B2 (en) * | 1997-08-01 | 2009-08-12 | キヤノン株式会社 | Manufacturing method of probe array |
US7135333B1 (en) | 1997-08-07 | 2006-11-14 | Thomas Jefferson University | Compositions that specifically bind to colorectal cancer cells and methods of using the same |
US6120995A (en) * | 1997-08-07 | 2000-09-19 | Thomas Jefferson University | Compositions that specifically bind to colorectal cancer cells and methods of using the same |
US6559296B2 (en) * | 1997-08-29 | 2003-05-06 | Olympus Optical Co., Ltd. | DNA capillary |
US6607878B2 (en) | 1997-10-06 | 2003-08-19 | Stratagene | Collections of uniquely tagged molecules |
WO1999019510A1 (en) * | 1997-10-10 | 1999-04-22 | President And Fellows Of Harvard College | Surface-bound, double-stranded dna protein arrays |
US6242246B1 (en) * | 1997-12-15 | 2001-06-05 | Somalogic, Inc. | Nucleic acid ligand diagnostic Biochip |
US20070166741A1 (en) * | 1998-12-14 | 2007-07-19 | Somalogic, Incorporated | Multiplexed analyses of test samples |
DE69839350T2 (en) | 1997-12-22 | 2009-06-04 | Pioneer-Hi-Bred International, Inc. | QTL MAPPING OF POPULATIONS IN PLANT BREEDING |
US6087102A (en) * | 1998-01-07 | 2000-07-11 | Clontech Laboratories, Inc. | Polymeric arrays and methods for their use in binding assays |
US6303848B1 (en) | 1998-01-16 | 2001-10-16 | Large Scale Biology Corporation | Method for conferring herbicide, pest, or disease resistance in plant hosts |
US20020164585A1 (en) * | 1998-01-16 | 2002-11-07 | Sean Chapman | Method for enhancing RNA or protein production using non-native 5' untranslated sequences in recombinant viral nucleic acids |
US20030166169A1 (en) * | 1998-01-16 | 2003-09-04 | Padgett Hal S. | Method for constructing viral nucleic acids in a cell-free manner |
US20030027173A1 (en) * | 1998-01-16 | 2003-02-06 | Della-Cioppa Guy | Method of determining the function of nucleotide sequences and the proteins they encode by transfecting the same into a host |
US6426185B1 (en) | 1998-01-16 | 2002-07-30 | Large Scale Biology Corporation | Method of compiling a functional gene profile in a plant by transfecting a nucleic acid sequence of a donor plant into a different host plant in an anti-sense orientation |
US6297010B1 (en) * | 1998-01-30 | 2001-10-02 | Genzyme Corporation | Method for detecting and identifying mutations |
US6150102A (en) * | 1998-02-03 | 2000-11-21 | Lucent Technologies Inc. | Method of generating nucleic acid oligomers of known composition |
US6537747B1 (en) | 1998-02-03 | 2003-03-25 | Lucent Technologies Inc. | Data transmission using DNA oligomers |
US6741956B1 (en) | 1998-02-03 | 2004-05-25 | Lucent Technologies Inc. | Analog computation using hybridization-capable oligomers |
AU2583899A (en) | 1998-02-04 | 1999-08-23 | Invitrogen Corporation | Microarrays and uses therefor |
US5994079A (en) | 1998-02-06 | 1999-11-30 | Digene Corporation | Direct detection of RNA mediated by reverse transcriptase lacking RNAse H function |
US7399589B2 (en) * | 1998-02-06 | 2008-07-15 | Digene Corporation | Immunological detection of RNA:DNA hybrids on microarrays |
US20040035690A1 (en) * | 1998-02-11 | 2004-02-26 | The Regents Of The University Of Michigan | Method and apparatus for chemical and biochemical reactions using photo-generated reagents |
CA2319587C (en) * | 1998-02-11 | 2004-09-21 | University Of Houston | Method and apparatus for chemical and biochemical reactions using photo-generated reagents |
CA2321070C (en) * | 1998-02-23 | 2010-04-06 | Wisconsin Alumni Research Foundation | Method and apparatus for synthesis of arrays of dna probes |
US6087103A (en) * | 1998-03-04 | 2000-07-11 | Lifespan Biosciences, Inc. | Tagged ligand arrays for identifying target-ligand interactions |
AU3217599A (en) * | 1998-03-31 | 1999-10-18 | Genzyme Corporation | Methods for the diagnosis and treatment of lung cancer |
US6048695A (en) * | 1998-05-04 | 2000-04-11 | Baylor College Of Medicine | Chemically modified nucleic acids and methods for coupling nucleic acids to solid support |
US6271957B1 (en) * | 1998-05-29 | 2001-08-07 | Affymetrix, Inc. | Methods involving direct write optical lithography |
EP1112377A4 (en) * | 1998-06-22 | 2004-11-10 | Univ California | Nucleic acid-coupled colorimetric analyte detectors |
US6235473B1 (en) | 1998-07-02 | 2001-05-22 | Orchid Biosciences, Inc. | Gene pen devices for array printing |
US6897073B2 (en) * | 1998-07-14 | 2005-05-24 | Zyomyx, Inc. | Non-specific binding resistant protein arrays and methods for making the same |
US6406921B1 (en) | 1998-07-14 | 2002-06-18 | Zyomyx, Incorporated | Protein arrays for high-throughput screening |
US20020119579A1 (en) * | 1998-07-14 | 2002-08-29 | Peter Wagner | Arrays devices and methods of use thereof |
US20030138973A1 (en) * | 1998-07-14 | 2003-07-24 | Peter Wagner | Microdevices for screening biomolecules |
US6682942B1 (en) | 1998-07-14 | 2004-01-27 | Zyomyx, Inc. | Microdevices for screening biomolecules |
US6780582B1 (en) * | 1998-07-14 | 2004-08-24 | Zyomyx, Inc. | Arrays of protein-capture agents and methods of use thereof |
US6576478B1 (en) | 1998-07-14 | 2003-06-10 | Zyomyx, Inc. | Microdevices for high-throughput screening of biomolecules |
WO2000004193A1 (en) | 1998-07-20 | 2000-01-27 | Yale University | Method for detecting nucleic acids using target-mediated ligation of bipartite primers |
CA2338401A1 (en) * | 1998-07-21 | 2000-02-03 | Burstein Laboratories, Inc | Optical disc-based assay devices and methods |
US6461812B2 (en) * | 1998-09-09 | 2002-10-08 | Agilent Technologies, Inc. | Method and multiple reservoir apparatus for fabrication of biomolecular arrays |
EP1114184A2 (en) * | 1998-09-15 | 2001-07-11 | Yale University | Molecular cloning using rolling circle amplification |
CA2342837A1 (en) | 1998-09-15 | 2000-03-23 | Yale University | Artificial long terminal repeat vectors |
US6475440B1 (en) | 1998-09-16 | 2002-11-05 | Clontech Laboratories, Inc. | Applicator for use in deposition of fluid samples onto a substrate surface |
US6203989B1 (en) | 1998-09-30 | 2001-03-20 | Affymetrix, Inc. | Methods and compositions for amplifying detectable signals in specific binding assays |
US6262216B1 (en) | 1998-10-13 | 2001-07-17 | Affymetrix, Inc. | Functionalized silicon compounds and methods for their synthesis and use |
US6541203B2 (en) * | 1998-11-23 | 2003-04-01 | President And Fellows Of Harvard College | Detecting structural or synthetic information about chemical compounds |
US6441152B1 (en) * | 1998-12-08 | 2002-08-27 | Boston Probes, Inc. | Methods, kits and compositions for the identification of nucleic acids electrostatically bound to matrices |
US6087112A (en) * | 1998-12-30 | 2000-07-11 | Oligos Etc. Inc. | Arrays with modified oligonucleotide and polynucleotide compositions |
US20030180789A1 (en) * | 1998-12-30 | 2003-09-25 | Dale Roderic M.K. | Arrays with modified oligonucleotide and polynucleotide compositions |
AU2877000A (en) * | 1999-02-10 | 2000-08-29 | University Of Maryland | Photo-induced nucleic acid hybridization |
EP2133426A3 (en) | 1999-03-11 | 2010-04-14 | Arborgen, Llc | Compositions and methods for the modification of gene transcription |
US7014994B1 (en) | 1999-03-19 | 2006-03-21 | Cornell Research Foundation,Inc. | Coupled polymerase chain reaction-restriction-endonuclease digestion-ligase detection reaction process |
US6506594B1 (en) * | 1999-03-19 | 2003-01-14 | Cornell Res Foundation Inc | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
US7518034B2 (en) * | 1999-03-25 | 2009-04-14 | Arborgen Llc | Compositions and methods for the modification of gene expression |
US6824866B1 (en) | 1999-04-08 | 2004-11-30 | Affymetrix, Inc. | Porous silica substrates for polymer synthesis and assays |
US6518056B2 (en) * | 1999-04-27 | 2003-02-11 | Agilent Technologies Inc. | Apparatus, systems and method for assaying biological materials using an annular format |
CA2373026C (en) * | 1999-05-04 | 2011-05-03 | Large Scale Biology Corporation | Viral expression vectors |
US6824987B1 (en) * | 1999-05-11 | 2004-11-30 | President And Fellows Of Harvard College | Small molecule printing |
PT1214594E (en) * | 1999-05-14 | 2006-11-30 | Iris Biotechnologies Inc | Reversible immobilization of ligands onto metal surfaces, their preparation and use in biochemical applications |
US6485690B1 (en) | 1999-05-27 | 2002-11-26 | Orchid Biosciences, Inc. | Multiple fluid sample processor and system |
WO2000079006A1 (en) * | 1999-06-17 | 2000-12-28 | Fred Hutchinson Cancer Research Center | Oligonucleotide arrays for high resolution hla typing |
US6346423B1 (en) | 1999-07-16 | 2002-02-12 | Agilent Technologies, Inc. | Methods and compositions for producing biopolymeric arrays |
US7144700B1 (en) * | 1999-07-23 | 2006-12-05 | Affymetrix, Inc. | Photolithographic solid-phase polymer synthesis |
CA2317179A1 (en) * | 1999-09-01 | 2001-03-01 | Affymetrix, Inc. | Macromolecular arrays on polymeric brushes and methods for preparing the same |
KR100858465B1 (en) | 1999-09-10 | 2008-09-16 | 제론 코포레이션 | Oligonucleotide n3'?p5' thiophosphoramidates: their synthesis and use |
AU1075701A (en) * | 1999-10-08 | 2001-04-23 | Protogene Laboratories, Inc. | Method and apparatus for performing large numbers of reactions using array assembly |
US6171797B1 (en) | 1999-10-20 | 2001-01-09 | Agilent Technologies Inc. | Methods of making polymeric arrays |
WO2001036442A1 (en) * | 1999-11-17 | 2001-05-25 | Jiuping Ji | Simultaneous detection of hbv, hcv and hiv in plasma samples using a multiplex capture assay |
NZ539430A (en) | 1999-12-10 | 2006-09-29 | Invitrogen Corp | Use of multiple recombination sites with unique specificity in recombinational cloning |
DE19962803A1 (en) * | 1999-12-23 | 2001-07-05 | Basf Ag | Process and device for mask-free production of biopolymers |
US6800439B1 (en) | 2000-01-06 | 2004-10-05 | Affymetrix, Inc. | Methods for improved array preparation |
US6833450B1 (en) | 2000-03-17 | 2004-12-21 | Affymetrix, Inc. | Phosphite ester oxidation in nucleic acid array preparation |
US20050119473A1 (en) * | 2000-03-17 | 2005-06-02 | Affymetrix, Inc. | Phosphite ester oxidation in nucleic acid array preparation |
US6806361B1 (en) | 2000-03-17 | 2004-10-19 | Affymetrix, Inc. | Methods of enhancing functional performance of nucleic acid arrays |
DE60142228D1 (en) | 2000-03-27 | 2010-07-08 | Univ Jefferson | COMPOSITIONS AND METHODS FOR IDENTIFYING AND TARGETING CANCER CELLS FROM THE DIGESTIVE CHANNEL |
IL151865A0 (en) * | 2000-03-31 | 2003-04-10 | Genentech Inc | Compositions and methods for detecting and quantifying gene expression |
US7157564B1 (en) | 2000-04-06 | 2007-01-02 | Affymetrix, Inc. | Tag nucleic acids and probe arrays |
AU2001259241A1 (en) * | 2000-04-26 | 2001-11-07 | Arcturus Engineering, Inc. | Laser capture microdissection (lcm) extraction device and device carrier and method for post-lcm fluid processing |
US8399383B2 (en) * | 2000-05-04 | 2013-03-19 | Yale University | Protein chips for high throughput screening of protein activity |
US7005259B1 (en) * | 2000-06-01 | 2006-02-28 | Affymetrix, Inc. | Methods for array preparation using substrate rotation |
AU6795201A (en) * | 2000-06-20 | 2002-01-02 | Genesis Res & Dev Corp Ltd | Nucleic acid sequences and methods for the modification of plant gene expression |
US20060166227A1 (en) * | 2000-06-20 | 2006-07-27 | Stephen Kingsmore | Protein expression profiling |
US9709559B2 (en) | 2000-06-21 | 2017-07-18 | Bioarray Solutions, Ltd. | Multianalyte molecular analysis using application-specific random particle arrays |
EP1311839B1 (en) | 2000-06-21 | 2006-03-01 | Bioarray Solutions Ltd | Multianalyte molecular analysis using application-specific random particle arrays |
US6323009B1 (en) * | 2000-06-28 | 2001-11-27 | Molecular Staging, Inc. | Multiply-primed amplification of nucleic acid sequences |
US7270954B1 (en) | 2000-06-30 | 2007-09-18 | Iris Biotechnologies, Inc. | Hybridization of target DNA with immobilized nucleic acid analogs |
US7091033B2 (en) * | 2000-07-21 | 2006-08-15 | Phase-1 Molecular Toxicology, Inc. | Array of toxicologically relevant canine genes and uses thereof |
DE10040857A1 (en) | 2000-08-11 | 2002-02-28 | Jens P Fuerste | Nucleic acid library or protein or peptide library |
US7022830B2 (en) * | 2000-08-17 | 2006-04-04 | Tripep Ab | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
WO2002013855A2 (en) | 2000-08-17 | 2002-02-21 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
US6680059B2 (en) * | 2000-08-29 | 2004-01-20 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
US6858590B2 (en) * | 2000-08-17 | 2005-02-22 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
US7198924B2 (en) | 2000-12-11 | 2007-04-03 | Invitrogen Corporation | Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites |
US6900013B1 (en) | 2000-08-25 | 2005-05-31 | Aviva Biosciences Corporation | Methods and compositions for identifying nucleic acid molecules using nucleolytic activities and hybridization |
EP1387894A4 (en) * | 2000-08-24 | 2006-10-11 | Aviva Biosciences Corp | Methods and compositions for identifying nucleic acid molecules using nucleolytic activities and hybridization |
US20020164634A1 (en) * | 2000-08-26 | 2002-11-07 | Perlegen Sciences, Inc. | Methods for reducing complexity of nucleic acid samples |
CA2421732A1 (en) * | 2000-09-11 | 2002-03-14 | Affymetrix, Inc. | Photocleavable protecting groups |
AU2001292728A1 (en) * | 2000-09-18 | 2002-03-26 | Thomas Jefferson University | Compositions and methods for identifying and targeting stomach and esophageal cancer cells |
US20020037359A1 (en) * | 2000-09-25 | 2002-03-28 | Mutz Mitchell W. | Focused acoustic energy in the preparation of peptide arrays |
US6849409B2 (en) * | 2000-10-16 | 2005-02-01 | Axxima Pharmaceuticals Ag | Cellular kinases involved in Cytomegalovirus infection and their inhibition |
US7001740B2 (en) * | 2000-11-08 | 2006-02-21 | Surface Logix, Inc. | Methods of arraying biological materials using peelable and resealable devices |
US6967074B2 (en) * | 2000-11-08 | 2005-11-22 | Surface Logix, Inc. | Methods of detecting immobilized biomolecules |
US7439056B2 (en) | 2000-11-08 | 2008-10-21 | Surface Logix Inc. | Peelable and resealable devices for arraying materials |
US7371563B2 (en) * | 2000-11-08 | 2008-05-13 | Surface Logix, Inc. | Peelable and resealable devices for biochemical assays |
US7351575B2 (en) * | 2000-11-08 | 2008-04-01 | Surface Logix, Inc. | Methods for processing biological materials using peelable and resealable devices |
US6803205B2 (en) * | 2000-11-08 | 2004-10-12 | Surface Logix, Inc. | Methods of measuring enzyme activity using peelable and resealable devices |
AU2002228872A1 (en) * | 2000-11-09 | 2002-05-21 | Burstein Technologies, Inc. | Disc drive system and methods for use with bio-discs |
GB0029590D0 (en) * | 2000-12-05 | 2001-01-17 | Univ Heriot Watt | Bio-strings |
AU2002241851A1 (en) * | 2001-01-11 | 2002-07-24 | Burstein Technologies, Inc. | Optical disc analysis system including related methods for biological and medical imaging |
WO2002062957A2 (en) * | 2001-02-07 | 2002-08-15 | Invitrogen Corporation | Ter sites and ter binding proteins |
WO2002099982A2 (en) * | 2001-03-01 | 2002-12-12 | Illumina, Inc. | Methods for improving signal detection from an array |
FR2822476B1 (en) | 2001-03-23 | 2004-04-02 | Aventis Pharma Sa | METHODS OF PURIFICATION AND DETECTION OF TARGET SEQUENCES OF DOUBLE-STRANDED DNA BY TRIPLE-HELICE INTERACTION |
AU2002247765B2 (en) * | 2001-03-28 | 2007-04-26 | Clondiag Chip Technologies Gmbh | Device for referencing fluorescence signals |
AU785425B2 (en) * | 2001-03-30 | 2007-05-17 | Genetic Technologies Limited | Methods of genomic analysis |
US7115726B2 (en) * | 2001-03-30 | 2006-10-03 | Perlegen Sciences, Inc. | Haplotype structures of chromosome 21 |
EP1249499A1 (en) * | 2001-04-10 | 2002-10-16 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method and device for the determination and selection of molecule-molecule interactions |
WO2002097109A2 (en) * | 2001-05-25 | 2002-12-05 | Invitrogen Corporation | Compositions and methods for extension of nucleic acids |
US20070184436A1 (en) * | 2001-06-07 | 2007-08-09 | Joel Myerson | Generic capture probe arrays |
US20030013109A1 (en) * | 2001-06-21 | 2003-01-16 | Ballinger Clinton T. | Hairpin sensors using quenchable fluorescing agents |
US7262063B2 (en) | 2001-06-21 | 2007-08-28 | Bio Array Solutions, Ltd. | Directed assembly of functional heterostructures |
EP1925672A1 (en) | 2001-06-22 | 2008-05-28 | Syngeta Participations AG | Abiotic stress responsive polynucleotides and polypeptides |
US6703235B2 (en) * | 2001-06-25 | 2004-03-09 | Board Of Regents, The University Of Texas System | Complex multicellular assemblies ex vivo |
US7221632B2 (en) * | 2001-07-12 | 2007-05-22 | Burstein Technologies, Inc. | Optical disc system and related detecting methods for analysis of microscopic structures |
US20030143612A1 (en) * | 2001-07-18 | 2003-07-31 | Pointilliste, Inc. | Collections of binding proteins and tags and uses thereof for nested sorting and high throughput screening |
CN1556924A (en) * | 2001-07-20 | 2004-12-22 | ̹�� | Optical analysis disc and related drive assembly for performing interactive centrifugation |
WO2003062783A2 (en) * | 2001-07-20 | 2003-07-31 | North Carolina State University | Light addressable electrochemical detection of duplex structures |
US6833441B2 (en) * | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
JP2005511012A (en) | 2001-08-10 | 2005-04-28 | セローノ ジェネティクス インスティテュート ソシエテ アノニム | Human cDNA and protein and uses thereof |
US20030165918A1 (en) * | 2001-08-17 | 2003-09-04 | Fuji Photo Film Co., Ltd. | Method for detecting nucleic acid |
US20080026367A9 (en) * | 2001-08-17 | 2008-01-31 | Perlegen Sciences, Inc. | Methods for genomic analysis |
US20030040129A1 (en) * | 2001-08-20 | 2003-02-27 | Shah Haresh P. | Binding assays using magnetically immobilized arrays |
AU2002332598A1 (en) * | 2001-08-22 | 2003-03-10 | Shengfeng Li | Compositions and methods for generating antigen-binding units |
US20030044798A1 (en) * | 2001-08-31 | 2003-03-06 | Lefkowitz Steven M. | Methods for generating ligand arrays via deposition of ligands onto olefin displaying substrates, and arrays produced thereby |
US20050147984A1 (en) * | 2001-08-31 | 2005-07-07 | Clondiag Chip Technologies Gmbh | Interaction detection on several probe arrays |
US6974671B1 (en) | 2001-09-12 | 2005-12-13 | Salk Institute For Biological Studies | Methods for indentifying compounds that modulate gluconeogenesis through the binding of CREB to the PGC-1 promoter |
US20060188875A1 (en) * | 2001-09-18 | 2006-08-24 | Perlegen Sciences, Inc. | Human genomic polymorphisms |
US20040053232A1 (en) * | 2001-10-05 | 2004-03-18 | Perlegen Sciences, Inc. | Haplotype structures of chromosome 21 |
DE10149684B4 (en) * | 2001-10-09 | 2005-02-17 | Clondiag Chip Technologies Gmbh | Device for holding a substance library carrier |
US20040002073A1 (en) | 2001-10-15 | 2004-01-01 | Li Alice Xiang | Multiplexed analysis of polymorphic loci by concurrent interrogation and enzyme-mediated detection |
EP1437368B8 (en) * | 2001-10-16 | 2014-01-08 | Federalnoe Gosudarstvennoe Byudzhetnoe Uchrezhdenie Nauki Institut Molekulyarnoi Biologi Im. V.A. Engelgardta Rossiiskoi Akademii Nauk | Composition for polymerising immobilisation of biological molecules and method for producing said composition |
US20040014064A1 (en) * | 2001-10-31 | 2004-01-22 | Brissette William H. | Therapeutics and diagnostics for disorders of erythropoiesis |
US7175983B2 (en) * | 2001-11-02 | 2007-02-13 | Abmaxis, Inc. | Adapter-directed display systems |
AU2002364894A1 (en) * | 2001-11-09 | 2003-06-30 | Neurogenetics, Inc. | Single nucleotide polymorphisms and mutations on alpha-2-macroglobulin |
US20080094974A1 (en) * | 2001-11-09 | 2008-04-24 | Burstein Technologies, Inc. | Optical disc system and related detecting methods for analysis of microscopic structures |
US20040067512A1 (en) * | 2001-11-09 | 2004-04-08 | Neurogenetics, Inc. | Single nucleotide polymorphisms and mutations on Alpha-2-Macroglobulin |
US20040023237A1 (en) * | 2001-11-26 | 2004-02-05 | Perelegen Sciences Inc. | Methods for genomic analysis |
CA2469403C (en) | 2001-12-05 | 2015-06-02 | Jonathan Mark Boutell | Protein arrays for allelic variants and uses thereof |
CN1281324C (en) * | 2001-12-19 | 2006-10-25 | 阿菲梅特里克斯公司 | Manufacturing process for array plate assembly |
US7011945B2 (en) * | 2001-12-21 | 2006-03-14 | Eastman Kodak Company | Random array of micro-spheres for the analysis of nucleic acids |
CN100343670C (en) * | 2001-12-21 | 2007-10-17 | 皇家飞利浦电子股份有限公司 | Sensor and method for measuring the areal density of magnetic nanoparticles on a micro-array |
CA2471658A1 (en) * | 2001-12-26 | 2003-07-10 | Canon Kabushiki Kaisha | Probe medium and method for fixing probe on a substrate |
WO2003060668A2 (en) * | 2002-01-14 | 2003-07-24 | Burstein Technologies, Inc. | Method and apparatus for visualizing data |
DE10201463B4 (en) | 2002-01-16 | 2005-07-21 | Clondiag Chip Technologies Gmbh | Reaction vessel for performing array method |
JP2005516336A (en) * | 2002-01-28 | 2005-06-02 | バースタイン テクノロジーズ,インコーポレイティド | Method and apparatus for logical triggering |
US20050002827A1 (en) * | 2002-01-29 | 2005-01-06 | Mcintyre Kevin Robert | Optical discs including equi-radial and/or spiral analysis zones and related disc drive systems and methods |
US20040053264A1 (en) * | 2002-02-01 | 2004-03-18 | Park Sung Sup | Clinical panel assay using DNA chips |
US7553619B2 (en) * | 2002-02-08 | 2009-06-30 | Qiagen Gmbh | Detection method using dissociated rolling circle amplification |
CA2476309A1 (en) * | 2002-02-15 | 2003-08-28 | Somalogic, Inc. | Methods and reagents for detecting target binding by nucleic acid ligands |
US7108891B2 (en) * | 2002-03-07 | 2006-09-19 | Eastman Kodak Company | Random array of microspheres |
US6916620B2 (en) * | 2002-03-15 | 2005-07-12 | Eastman Kodak Company | Random array of micro-spheres for the analysis of nucleic acid using enzyme digestion |
US20030186302A1 (en) * | 2002-03-29 | 2003-10-02 | Yixin Wang | Colorectal cancer diagnostics |
US20030194709A1 (en) * | 2002-04-10 | 2003-10-16 | Xing Yang | Hydrophobic zone device |
US20040023275A1 (en) * | 2002-04-29 | 2004-02-05 | Perlegen Sciences, Inc. | Methods for genomic analysis |
ATE534035T1 (en) | 2002-05-08 | 2011-12-15 | Northwest Biotherapeutics Inc | QUALITY TESTS FOR ANTIGEN-PRESENTING CELLS |
US7011971B2 (en) * | 2002-06-03 | 2006-03-14 | Eastman Kodak Company | Method of making random array of microspheres using enzyme digestion |
US6730515B2 (en) | 2002-06-11 | 2004-05-04 | Eastman Kodak Company | Micro-array calibration means |
US7135343B2 (en) * | 2002-06-17 | 2006-11-14 | Agilent Technologies, Inc. | Biomolecule resistant and their methods of use in assays |
US20030231986A1 (en) * | 2002-06-18 | 2003-12-18 | Eastman Kodak Company | Micro-array identification means |
US7332273B2 (en) | 2002-06-20 | 2008-02-19 | Affymetrix, Inc. | Antireflective coatings for high-resolution photolithographic synthesis of DNA arrays |
US7504215B2 (en) | 2002-07-12 | 2009-03-17 | Affymetrix, Inc. | Nucleic acid labeling methods |
AU2003257109A1 (en) * | 2002-08-05 | 2004-02-23 | Invitrogen Corporation | Compositions and methods for molecular biology |
US20050233473A1 (en) * | 2002-08-16 | 2005-10-20 | Zyomyx, Inc. | Methods and reagents for surface functionalization |
US20050118616A1 (en) * | 2002-08-16 | 2005-06-02 | Kawashima Tadashi R. | Amplification of target nucleotide sequence without polymerase chain reaction |
US7157228B2 (en) * | 2002-09-09 | 2007-01-02 | Bioarray Solutions Ltd. | Genetic analysis and authentication |
AU2003270898A1 (en) * | 2002-09-27 | 2004-04-19 | Nimblegen Systems, Inc. | Microarray with hydrophobic barriers |
US20040110212A1 (en) * | 2002-09-30 | 2004-06-10 | Mccormick Mark | Microarrays with visual alignment marks |
AU2003301825A1 (en) * | 2002-10-31 | 2004-06-07 | Pfizer Products, Inc. | Panels of molecular targets differentially expressed during cd8+ t-cell priming |
US20040086892A1 (en) * | 2002-11-06 | 2004-05-06 | Crothers Donald M. | Universal tag assay |
US7526114B2 (en) | 2002-11-15 | 2009-04-28 | Bioarray Solutions Ltd. | Analysis, secure access to, and transmission of array images |
EP1565578A4 (en) * | 2002-11-18 | 2007-11-07 | Panomics Inc | Rnai-based sensors, caged interfering rnas, and methods of use thereof |
DE10253966B4 (en) * | 2002-11-19 | 2005-03-24 | Clondiag Chip Technologies Gmbh | Microarray-based method for the amplification and detection of nucleic acids in a continuous process |
AU2003302472B2 (en) * | 2002-11-22 | 2010-10-21 | The Johns Hopkins University | Target for therapy of cognitive impairment |
US20040106114A1 (en) * | 2002-12-02 | 2004-06-03 | Eastman Kodak Company | Simplified detection process for colored bead random microarrays |
US20040109045A1 (en) * | 2002-12-06 | 2004-06-10 | Eastman Kodak Company | Print head for micro-deposition of bio-molecules |
US20040110136A1 (en) * | 2002-12-09 | 2004-06-10 | Eastman Kodak Company | Micro-array calibration system and method |
US20040120859A1 (en) * | 2002-12-20 | 2004-06-24 | Kocher Thomas E. | Biomolecular micro-deposition system |
US9487823B2 (en) | 2002-12-20 | 2016-11-08 | Qiagen Gmbh | Nucleic acid amplification |
US6977153B2 (en) * | 2002-12-31 | 2005-12-20 | Qiagen Gmbh | Rolling circle amplification of RNA |
US20040180369A1 (en) * | 2003-01-16 | 2004-09-16 | North Carolina State University | Photothermal detection of nucleic acid hybridization |
ATE410450T1 (en) * | 2003-01-22 | 2008-10-15 | Bionanophotonics As | LIGHT-INDUCED IMMOBILIZATION |
WO2004071436A2 (en) * | 2003-02-10 | 2004-08-26 | Thomas Jefferson University | The use of gcc ligands |
US7166451B1 (en) * | 2003-02-24 | 2007-01-23 | The Ohio State University | Immobilization of enzyme on a fibrous matrix |
US20090124514A1 (en) * | 2003-02-26 | 2009-05-14 | Perlegen Sciences, Inc. | Selection probe amplification |
US20060183132A1 (en) * | 2005-02-14 | 2006-08-17 | Perlegen Sciences, Inc. | Selection probe amplification |
US20040235019A1 (en) * | 2003-03-06 | 2004-11-25 | Agouron Pharmaceuticals, Inc. | Diagnostics and therapeutics for the gene expression signature of PPAR-gamma receptor ligand |
JP2004279196A (en) * | 2003-03-14 | 2004-10-07 | Dainippon Printing Co Ltd | Substrate for bio-micro-array and bio-micro-array |
US8043834B2 (en) | 2003-03-31 | 2011-10-25 | Qiagen Gmbh | Universal reagents for rolling circle amplification and methods of use |
US20040191782A1 (en) * | 2003-03-31 | 2004-09-30 | Yixin Wang | Colorectal cancer prognostics |
DE10315074A1 (en) * | 2003-04-02 | 2004-10-14 | Clondiag Chip Technologies Gmbh | Device for the duplication and detection of nucleic acids |
US7348420B2 (en) | 2003-04-25 | 2008-03-25 | North Carolina State University | Lactobacillus acidophilus nucleic acid sequences encoding cell surface protein homologues and uses therefore |
MXPA05011404A (en) * | 2003-04-25 | 2006-05-31 | Johnson & Johnson | Preservation of rna in a biological sample. |
US20040248323A1 (en) * | 2003-06-09 | 2004-12-09 | Protometrix, Inc. | Methods for conducting assays for enzyme activity on protein microarrays |
WO2005000098A2 (en) | 2003-06-10 | 2005-01-06 | The Trustees Of Boston University | Detection methods for disorders of the lung |
EP2319863A1 (en) | 2003-06-23 | 2011-05-11 | North Carolina State University | Lactobacillus acidophilus nucleic acids encoding fructo-oligosaccharide utilization compounds and uses thereof |
US7642064B2 (en) * | 2003-06-24 | 2010-01-05 | Ventana Medical Systems, Inc. | Enzyme-catalyzed metal deposition for the enhanced detection of analytes of interest |
ATE437369T1 (en) * | 2003-06-24 | 2009-08-15 | Ventana Med Syst Inc | ENZYME-CATALYzed METAL DEPOSITION FOR ENHANCED IN-SITU DETECTION OF IMMUNOHISTOLOGICAL EPITOPES AND NUCLEIC ACID SEQUENCES |
US7034941B2 (en) * | 2003-06-26 | 2006-04-25 | Eastman Kodak Company | Color detection using spectroscopic imaging and processing in random array of microspheres |
US6947142B2 (en) * | 2003-06-26 | 2005-09-20 | Eastman Kodak Company | Color detection in random array of microspheres |
US20050019944A1 (en) * | 2003-07-23 | 2005-01-27 | Eastman Kodak Company | Colorable microspheres for DNA and protein microarray |
US20050019745A1 (en) * | 2003-07-23 | 2005-01-27 | Eastman Kodak Company | Random array of microspheres |
US6914106B2 (en) * | 2003-07-23 | 2005-07-05 | Eastman Kodak Company | Polymer microspheres containing latent colorants and method of preparation |
US20050059024A1 (en) | 2003-07-25 | 2005-03-17 | Ambion, Inc. | Methods and compositions for isolating small RNA molecules |
US20050059054A1 (en) | 2003-07-25 | 2005-03-17 | Richard Conrad | Methods and compositions for preparing RNA from a fixed sample |
US6995206B2 (en) * | 2003-07-28 | 2006-02-07 | Hewlett-Packard Development Company, L.P. | Methods of preparing latex particulates with reactive functional groups |
US20050100911A1 (en) * | 2003-08-06 | 2005-05-12 | Perlegen Sciences, Inc. | Methods for enriching populations of nucleic acid samples |
US7927796B2 (en) | 2003-09-18 | 2011-04-19 | Bioarray Solutions, Ltd. | Number coding for identification of subtypes of coded types of solid phase carriers |
WO2005031305A2 (en) | 2003-09-22 | 2005-04-07 | Bioarray Solutions, Ltd. | Surface immobilized polyelectrolyte with multiple functional groups capable of covalently bonding to biomolecules |
US20050227251A1 (en) | 2003-10-23 | 2005-10-13 | Robert Darnell | Method of purifying RNA binding protein-RNA complexes |
US7563569B2 (en) | 2003-10-28 | 2009-07-21 | Michael Seul | Optimization of gene expression analysis using immobilized capture probes |
JP2007509629A (en) | 2003-10-29 | 2007-04-19 | バイオアレイ ソリューションズ リミテッド | Complex nucleic acid analysis by cleavage of double-stranded DNA |
WO2005042783A1 (en) * | 2003-10-30 | 2005-05-12 | North Carolina State University | Temperature-jump enhanced electrochemical detection of nucleic acid hybridization |
US20100000881A1 (en) * | 2003-10-30 | 2010-01-07 | North Carolina State University | Electrochemical detection of nucleic acid hybridization |
US8637650B2 (en) | 2003-11-05 | 2014-01-28 | Genovoxx Gmbh | Macromolecular nucleotide compounds and methods for using the same |
WO2005049848A2 (en) * | 2003-11-12 | 2005-06-02 | Geneohm Sciences, Inc. | Nucleic acid hybridization methods |
US20050106712A1 (en) * | 2003-11-14 | 2005-05-19 | Eastman Kodak Company | Yellow low fluorescence dye for coated optical bead random array DNA analysis |
US20050106574A1 (en) * | 2003-11-14 | 2005-05-19 | Eastman Kodak Company | Magenta low fluorescence dye for coated optical bead random array DNA analysis |
US20050106711A1 (en) * | 2003-11-14 | 2005-05-19 | Eastman Kodak Company | Cyan low fluorescence dye for coated optical bead random array DNA analysis |
DK1709198T3 (en) | 2003-11-26 | 2013-09-02 | Advandx Inc | Peptide Nucleic Acid Probes for the Analysis of Certain Staphylococcus Species |
JP2007512838A (en) | 2003-12-01 | 2007-05-24 | インヴィトロジェン コーポレーション | Nucleic acid molecules containing recombination sites and methods of use thereof |
CA2497324A1 (en) | 2004-02-17 | 2005-08-17 | Affymetrix, Inc. | Methods for fragmenting and labelling dna |
US20050186577A1 (en) | 2004-02-20 | 2005-08-25 | Yixin Wang | Breast cancer prognostics |
US7459289B2 (en) | 2004-03-08 | 2008-12-02 | North Carolina State University | Lactobacillus acidophilus nucleic acid sequences encoding carbohydrate utilization-related proteins and uses therefor |
EP1720015A1 (en) * | 2004-03-17 | 2006-11-08 | Matsushita Electric Industrial Co., Ltd. | Process for producing biochip, probe solution, and biochip |
US7919277B2 (en) | 2004-04-28 | 2011-04-05 | Danisco A/S | Detection and typing of bacterial strains |
US20050244984A1 (en) * | 2004-04-28 | 2005-11-03 | Parker Russell A | Methods and compositions for calibrating chemical array readers |
DE102005052713A1 (en) | 2005-11-04 | 2007-05-16 | Clondiag Chip Tech Gmbh | Apparatus and method for detecting molecular interactions |
DE102004022263A1 (en) | 2004-05-06 | 2005-12-15 | Clondiag Chip Technologies Gmbh | Apparatus and method for detecting molecular interactions |
EP2290071B1 (en) | 2004-05-28 | 2014-12-31 | Asuragen, Inc. | Methods and compositions involving microRNA |
US20060009038A1 (en) * | 2004-07-12 | 2006-01-12 | International Business Machines Corporation | Processing for overcoming extreme topography |
US7848889B2 (en) | 2004-08-02 | 2010-12-07 | Bioarray Solutions, Ltd. | Automated analysis of multiplexed probe-target interaction patterns: pattern matching and allele identification |
US20060073506A1 (en) | 2004-09-17 | 2006-04-06 | Affymetrix, Inc. | Methods for identifying biological samples |
US7314542B2 (en) * | 2004-09-23 | 2008-01-01 | Nanogen, Inc. | Methods and materials for optimization of electronic transportation and hybridization reactions |
EP1645640B1 (en) | 2004-10-05 | 2013-08-21 | Affymetrix, Inc. | Method for detecting chromosomal translocations |
CN101080487B (en) | 2004-10-07 | 2012-11-14 | 阿戈斯治疗公司 | Mature dendritic cell compositions and methods for culturing same |
US7682782B2 (en) | 2004-10-29 | 2010-03-23 | Affymetrix, Inc. | System, method, and product for multiple wavelength detection using single source excitation |
EP1652580A1 (en) | 2004-10-29 | 2006-05-03 | Affymetrix, Inc. | High throughput microarray, package assembly and methods of manufacturing arrays |
DE102004056735A1 (en) | 2004-11-09 | 2006-07-20 | Clondiag Chip Technologies Gmbh | Device for performing and analyzing microarray experiments |
EP2281887A1 (en) | 2004-11-12 | 2011-02-09 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
CA2589782A1 (en) * | 2004-11-30 | 2006-06-08 | Veridex Llc | Lung cancer prognostics |
US7547775B2 (en) * | 2004-12-31 | 2009-06-16 | Affymetrix, Inc. | Parallel preparation of high fidelity probes in an array format |
US8338093B2 (en) * | 2004-12-31 | 2012-12-25 | Affymetrix, Inc. | Primer array synthesis and validation |
US20060183893A1 (en) * | 2005-01-25 | 2006-08-17 | North Don A | Nucleic acids for apoptosis of cancer cells |
JP2008527996A (en) * | 2005-01-25 | 2008-07-31 | スカイ、ジェネティクス、インク | Nucleic acids for apoptosis of cancer cells |
WO2006083751A2 (en) * | 2005-01-31 | 2006-08-10 | Pacific Biosciences Of California, Inc. | Use of reversible extension terminator in nucleic acid sequencing |
US20060194215A1 (en) * | 2005-02-28 | 2006-08-31 | Kronick Mel N | Methods, reagents and kits for reusing arrays |
US20060257902A1 (en) * | 2005-03-25 | 2006-11-16 | Ambion, Inc. | Methods and compositions for depleting abundant RNA transcripts |
US8309303B2 (en) | 2005-04-01 | 2012-11-13 | Qiagen Gmbh | Reverse transcription and amplification of RNA with simultaneous degradation of DNA |
WO2006108135A2 (en) * | 2005-04-04 | 2006-10-12 | Veridex, Llc | Laser microdissection and microarray analysis of breast tumors reveal estrogen receptor related genes and pathways |
US20060229819A1 (en) * | 2005-04-12 | 2006-10-12 | Eastman Kodak Company | Method for imaging an array of microspheres |
US20060228720A1 (en) * | 2005-04-12 | 2006-10-12 | Eastman Kodak Company | Method for imaging an array of microspheres |
US20060228719A1 (en) * | 2005-04-12 | 2006-10-12 | Eastman Kodak Company | Method for imaging an array of microspheres using specular illumination |
EP2360278A1 (en) | 2005-04-14 | 2011-08-24 | Trustees Of Boston University | Diagnostic for lung disorders using class prediction |
CN101198689A (en) | 2005-04-15 | 2008-06-11 | 北卡罗来纳州大学 | Methods and compositions to modulate adhesion and stress tolerance in bacteria |
CA2618429A1 (en) | 2005-05-25 | 2007-03-22 | Tripep Ab | A hepatitis c virus non-structural ns3/4a fusion gene |
US8486629B2 (en) | 2005-06-01 | 2013-07-16 | Bioarray Solutions, Ltd. | Creation of functionalized microparticle libraries by oligonucleotide ligation or elongation |
WO2007000163A1 (en) * | 2005-06-27 | 2007-01-04 | Bionanophotonics A/S | Immobilisation of polypeptides by irradiation |
US7666584B2 (en) * | 2005-09-01 | 2010-02-23 | Philadelphia Health & Education Coporation | Identification of a pin specific gene and protein (PIN-1) useful as a diagnostic treatment for prostate cancer |
EP1762627A1 (en) | 2005-09-09 | 2007-03-14 | Qiagen GmbH | Method for the activation of a nucleic acid for performing a polymerase reaction |
US7608395B2 (en) * | 2005-09-15 | 2009-10-27 | Baylor Research Institute | Systemic lupus erythematosus diagnostic assay |
EP2402758B1 (en) | 2005-09-19 | 2014-09-10 | Janssen Diagnostics, LLC | Methods and uses for identifying the origin of a carcinoma of unknown primary origin |
US7763423B2 (en) * | 2005-09-30 | 2010-07-27 | Pacific Biosciences Of California, Inc. | Substrates having low density reactive groups for monitoring enzyme activity |
WO2007047408A2 (en) * | 2005-10-12 | 2007-04-26 | Pathologica, Llc. | Promac signature application |
US7634363B2 (en) | 2005-12-07 | 2009-12-15 | Affymetrix, Inc. | Methods for high throughput genotyping |
EP1960547A2 (en) | 2005-12-08 | 2008-08-27 | Novartis AG | Effects of inhibitors of fgfr3 on gene transcription |
US20070141584A1 (en) * | 2005-12-20 | 2007-06-21 | Roberts Douglas N | Methods for assessment of native chromatin on microarrays |
US20070255054A1 (en) * | 2005-12-30 | 2007-11-01 | Affymetrix, Inc. | Oligonucleotide synthesis with intermittent and post synthetic oxidation |
JP2009522576A (en) * | 2006-01-03 | 2009-06-11 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Small molecule printing |
ES2644499T3 (en) * | 2006-01-17 | 2017-11-29 | Somalogic, Inc. | Kits comprising aptamers |
EP1986661B1 (en) | 2006-02-08 | 2018-08-29 | Genzyme Corporation | Gene therapy for niemann-pick disease type a |
US20090061454A1 (en) | 2006-03-09 | 2009-03-05 | Brody Jerome S | Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells |
BRPI0709396A2 (en) * | 2006-03-13 | 2011-07-05 | Veridex Llc | primary cell propagation |
WO2007121054A2 (en) * | 2006-03-27 | 2007-10-25 | Sky Genetics, Inc. | Nucleic acids for apoptosis of cancer cells |
US8975216B2 (en) | 2006-03-30 | 2015-03-10 | Pacific Biosciences Of California | Articles having localized molecules disposed thereon and methods of producing same |
US20080050747A1 (en) * | 2006-03-30 | 2008-02-28 | Pacific Biosciences Of California, Inc. | Articles having localized molecules disposed thereon and methods of producing and using same |
EP2029780A4 (en) * | 2006-06-16 | 2010-03-31 | Pacific Biosciences California | Controlled initiation of primer extension |
AU2007284651B2 (en) | 2006-08-09 | 2014-03-20 | Institute For Systems Biology | Organ-specific proteins and methods of their use |
AU2007299828C1 (en) | 2006-09-19 | 2014-07-17 | Interpace Diagnostics, Llc | MicroRNAs differentially expressed in pancreatic diseases and uses thereof |
JP2010510964A (en) | 2006-09-19 | 2010-04-08 | アシュラジェン インコーポレイテッド | MiR-15, miR-26, miR-31, miR-145, miR-147, miR-188, miR-215, miR-216, miR-331, mmu-miR-292 as targets for therapeutic intervention Genes and pathways regulated by 3p |
EP2069377A4 (en) | 2006-09-27 | 2009-11-11 | Univ California | Methods and compositions for the treatment of skin diseases and disorders |
US9845494B2 (en) | 2006-10-18 | 2017-12-19 | Affymetrix, Inc. | Enzymatic methods for genotyping on arrays |
DE102006035393A1 (en) | 2006-11-02 | 2008-05-15 | Signature Diagnostics Ag | Prognostic markers for the classification of the three-year progression-free survival of patients with colon carcinoma based on expression profiles of biological samples |
DE102006035392A1 (en) | 2006-11-02 | 2008-10-16 | Signature Diagnostics Ag | Prognostic markers for the prediction of five-year progression-free survival of patients with colon carcinoma based on expression profiles of biological samples |
DE102006035388A1 (en) * | 2006-11-02 | 2008-05-15 | Signature Diagnostics Ag | Prognostic markers for the classification of colon carcinomas based on expression profiles of biological samples |
US8293684B2 (en) * | 2006-11-29 | 2012-10-23 | Exiqon | Locked nucleic acid reagents for labelling nucleic acids |
AU2007333109A1 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Functions and targets of let-7 micro RNAs |
US20080182328A1 (en) * | 2006-12-19 | 2008-07-31 | The Burnham Institute | Mammalian extraembryonic endoderm cells and methods of isolation |
US20100248975A1 (en) * | 2006-12-29 | 2010-09-30 | Gunjan Tiwari | Fluorogenic peptide substrate arrays for highly multiplexed, real-time monitoring of kinase activities |
US7947447B2 (en) | 2007-01-16 | 2011-05-24 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
US20110136099A1 (en) * | 2007-01-16 | 2011-06-09 | Somalogic, Inc. | Multiplexed Analyses of Test Samples |
US8975026B2 (en) | 2007-01-16 | 2015-03-10 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
US7964356B2 (en) * | 2007-01-16 | 2011-06-21 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
US7855054B2 (en) * | 2007-01-16 | 2010-12-21 | Somalogic, Inc. | Multiplexed analyses of test samples |
US7572990B2 (en) * | 2007-03-30 | 2009-08-11 | Intermec Ip Corp. | Keypad overlay membrane |
US20080274458A1 (en) * | 2007-05-01 | 2008-11-06 | Latham Gary J | Nucleic acid quantitation methods |
US8200440B2 (en) * | 2007-05-18 | 2012-06-12 | Affymetrix, Inc. | System, method, and computer software product for genotype determination using probe array data |
DE102007031526B4 (en) | 2007-07-06 | 2010-07-08 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Use of an anode in a fuel cell for the oxidation of ethanol and / or at least one C3 to C10-containing alcohol |
EP2185195A2 (en) * | 2007-08-16 | 2010-05-19 | Tripep Ab | Immunogen platform |
EP2195451A4 (en) * | 2007-08-28 | 2011-01-19 | Merck Sharp & Dohme | Expression profiles of biomarker genes in notch mediated cancers |
DK2548962T3 (en) | 2007-09-19 | 2016-04-11 | Applied Biosystems Llc | Sirna sequence-independent modification formats to reduce off-target phenotype effects in RNAI and stabilized forms thereof |
US8906700B2 (en) | 2007-11-06 | 2014-12-09 | Ambergen, Inc. | Methods and compositions for phototransfer |
DE102007062154A1 (en) | 2007-12-21 | 2009-06-25 | Emc Microcollections Gmbh | Process for the preparation and use of stochastically arranged arrays of test substances |
US20090192045A1 (en) * | 2008-01-22 | 2009-07-30 | Yuqiu Jiang | Molecular staging of stage ii and iii colon cancer and prognosis |
US20090233809A1 (en) * | 2008-03-04 | 2009-09-17 | Affymetrix, Inc. | Resequencing methods for identification of sequence variants |
CN101918597B (en) | 2008-03-11 | 2013-09-18 | 国立癌中心 | Method for measuring chromosome, gene or specific nucleotide sequence copy numbers using SNP array |
US7932036B1 (en) | 2008-03-12 | 2011-04-26 | Veridex, Llc | Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase |
WO2009130588A2 (en) * | 2008-04-22 | 2009-10-29 | Tripep Ab | Immunogen platform |
US8258111B2 (en) | 2008-05-08 | 2012-09-04 | The Johns Hopkins University | Compositions and methods related to miRNA modulation of neovascularization or angiogenesis |
WO2010096036A2 (en) | 2008-05-14 | 2010-08-26 | Millennium Pharmaceuticals, Inc. | Methods and kits for monitoring the effects of immunomodulators on adaptive immunity |
US8703416B2 (en) | 2008-07-17 | 2014-04-22 | Somalogic, Inc. | Method for purification and identification of sperm cells |
CA2742324A1 (en) | 2008-10-30 | 2010-06-03 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Methods for assessing rna patterns |
JP2012508577A (en) | 2008-11-12 | 2012-04-12 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス | Method and system for using exosomes to determine phenotype |
US20100161607A1 (en) | 2008-12-22 | 2010-06-24 | Jasjit Singh | System and method for analyzing genome data |
ES2805347T3 (en) | 2009-02-11 | 2021-02-11 | Caris Mpi Inc | Molecular profiling of tumors |
WO2010096658A1 (en) | 2009-02-19 | 2010-08-26 | The Cleveland Clinic Foundation | Corin as a marker for heart failure |
WO2010101627A2 (en) | 2009-03-02 | 2010-09-10 | Massachusetts Institute Of Technology | Methods and systems for treatment and/or diagnosis |
EP3255146B1 (en) | 2009-03-16 | 2019-05-15 | Pangu Biopharma Limited | Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities |
CN102449143B (en) | 2009-03-31 | 2017-11-14 | Atyr医药公司 | Include the composition and method of the aspartoyl tRNA synzyme with unconventional bioactivity |
WO2010125566A2 (en) | 2009-04-27 | 2010-11-04 | Technion Research And Development Foundation Ltd. | Markers for cancer detection |
US20100298171A1 (en) * | 2009-05-22 | 2010-11-25 | Affymetrix, Inc. | Apparatus for polymer synthesis |
US8632975B2 (en) | 2009-06-05 | 2014-01-21 | Life Technologies Corporation | Nucleotide transient binding for sequencing methods |
US8501406B1 (en) | 2009-07-14 | 2013-08-06 | Pacific Biosciences Of California, Inc. | Selectively functionalized arrays |
US9771618B2 (en) * | 2009-08-19 | 2017-09-26 | Bioarray Genetics, Inc. | Methods for treating breast cancer |
AU2010315400B2 (en) | 2009-10-27 | 2016-07-21 | Caris Mpi, Inc. | Molecular profiling for personalized medicine |
AU2010324594B2 (en) | 2009-11-30 | 2016-09-15 | Caris Life Sciences Switzerland Holdings Gmbh | Methods and systems for isolating, storing, and analyzing vesicles |
US8501122B2 (en) | 2009-12-08 | 2013-08-06 | Affymetrix, Inc. | Manufacturing and processing polymer arrays |
US8835358B2 (en) | 2009-12-15 | 2014-09-16 | Cellular Research, Inc. | Digital counting of individual molecules by stochastic attachment of diverse labels |
US20110143966A1 (en) * | 2009-12-15 | 2011-06-16 | Affymetrix, Inc. | Surface Modifications and Methods for their Synthesis and Use |
FR2954349A1 (en) | 2009-12-22 | 2011-06-24 | Agronomique Inst Nat Rech | SULFATASE SELECTIVELY MODIFYING GLYCOSAMINOGLYCANS |
WO2011088226A2 (en) | 2010-01-13 | 2011-07-21 | Caris Life Sciences Luxembourg Holdings | Detection of gastrointestinal disorders |
CA2791905A1 (en) | 2010-03-01 | 2011-09-09 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Biomarkers for theranostics |
AU2011223527B2 (en) | 2010-03-03 | 2014-11-13 | Somalogic Operating Co., Inc. | Aptamers to 4-1BB and their use in treating diseases and disorders |
EP2542678B1 (en) | 2010-03-04 | 2017-04-12 | InteRNA Technologies B.V. | A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS THERAPEUTIC USES IN CANCER ASSOCIATED WITH EMT |
EP2556172A4 (en) | 2010-04-06 | 2013-10-30 | Caris Life Sciences Luxembourg Holdings | Circulating biomarkers for disease |
JP6012591B2 (en) | 2010-04-12 | 2016-10-26 | ソマロジック, インコーポレイテッドSomaLogic, Inc. | Aptamers to β-NGF and their use in the treatment of β-NGF mediated diseases and disorders |
WO2011139714A2 (en) | 2010-04-26 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase |
US8961960B2 (en) | 2010-04-27 | 2015-02-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases |
EP2563911B1 (en) | 2010-04-28 | 2021-07-21 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases |
US9034320B2 (en) | 2010-04-29 | 2015-05-19 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Valyl-tRNA synthetases |
WO2011135459A2 (en) | 2010-04-29 | 2011-11-03 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy |
AU2011248490B2 (en) | 2010-04-29 | 2016-11-10 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases |
US8981045B2 (en) | 2010-05-03 | 2015-03-17 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-tRNA synthetases |
JP5976638B2 (en) | 2010-05-03 | 2016-08-23 | エータイアー ファーマ, インコーポレイテッド | Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of arginyl tRNA synthetase |
EP2566495B1 (en) | 2010-05-03 | 2017-03-01 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases |
US9062302B2 (en) | 2010-05-04 | 2015-06-23 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex |
EP2568996B1 (en) | 2010-05-14 | 2017-10-04 | aTyr Pharma, Inc. | Therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases |
US9034598B2 (en) | 2010-05-17 | 2015-05-19 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases |
WO2011146725A1 (en) | 2010-05-19 | 2011-11-24 | Bayer Healthcare Llc | Biomarkers for a multikinase inhibitor |
EP2388336A1 (en) | 2010-05-19 | 2011-11-23 | Signature Diagnostics AG | Method and kits for diagnosing colorectal cancer |
AU2011258106B2 (en) | 2010-05-27 | 2017-02-23 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases |
CN103118694B (en) | 2010-06-01 | 2016-08-03 | Atyr医药公司 | The discovery for the treatment of, diagnosis and the antibody compositions relevant to the protein fragments of lysyl-tRNA synzyme |
WO2012005572A1 (en) | 2010-07-06 | 2012-01-12 | Interna Technologies Bv | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
EP2593125B1 (en) | 2010-07-12 | 2017-11-01 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases |
WO2012009711A2 (en) | 2010-07-16 | 2012-01-19 | Tocagen Inc. | Retrovirus detection |
US9029506B2 (en) | 2010-08-25 | 2015-05-12 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-tRNA synthetases |
BR112013012265A2 (en) | 2010-11-17 | 2016-08-02 | Asuragen Inc | mirnas as biomarkers to distinguish benign from malignant thyroid neoplasms |
EP2474617A1 (en) | 2011-01-11 | 2012-07-11 | InteRNA Technologies BV | Mir for treating neo-angiogenesis |
EP3369828B1 (en) | 2011-02-07 | 2020-07-15 | The Governing Council Of The University Of Toronto | Bioprobes and methods of use thereof |
WO2012158238A2 (en) | 2011-02-28 | 2012-11-22 | University Of Iowa Research Foundation | Anti-müllerian hormone changes in pregnancy and prediction ofadverse pregnancy outcomes and gender |
US8759036B2 (en) | 2011-03-21 | 2014-06-24 | Affymetrix, Inc. | Methods for synthesizing pools of probes |
JP2014510533A (en) | 2011-03-28 | 2014-05-01 | ノバルティス アーゲー | Markers associated with cyclin-dependent kinase inhibitors |
EP2520661A1 (en) | 2011-05-02 | 2012-11-07 | Rheinische Friedrich-Wilhelms-Universität Bonn | Blood-based gene expression signatures in lung cancer |
EP2527459A1 (en) | 2011-05-02 | 2012-11-28 | Rheinische Friedrich-Wilhelms-Universität Bonn | Blood-based gene detection of non-small cell lung cancer |
EP2710147A1 (en) | 2011-05-18 | 2014-03-26 | Rheinische Friedrich-Wilhelms-Universität Bonn | Molecular analysis of acute myeloid leukemia |
EP2524967A1 (en) | 2011-05-19 | 2012-11-21 | Signature Diagnostics AG | Methods and kits for diagnosing colorectal cancer |
EP2524968A1 (en) | 2011-05-19 | 2012-11-21 | Signature Diagnostics AG | Methods and kits for diagnosing colorectal cancer |
WO2012163541A1 (en) | 2011-06-01 | 2012-12-06 | Medical Prognosis Institute A/S | Methods and devices for prognosis of cancer relapse |
US9435812B2 (en) | 2011-08-31 | 2016-09-06 | Ventana Medical Systems, Inc. | Expression of ETS related gene (ERG) and phosphatase and tensin homolog (PTEN) correlates with prostate cancer capsular penetration |
US9644241B2 (en) | 2011-09-13 | 2017-05-09 | Interpace Diagnostics, Llc | Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease |
WO2013063519A1 (en) | 2011-10-26 | 2013-05-02 | Asuragen, Inc. | Methods and compositions involving mirna expression levels for distinguishing pancreatic cysts |
WO2013063544A1 (en) | 2011-10-27 | 2013-05-02 | Asuragen, Inc. | Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors |
CN106978487A (en) | 2011-10-28 | 2017-07-25 | 米伦纽姆医药公司 | Biomarkers of response to inhibitors of NEDD8 activating enzyme (NAE) |
EP2776043B1 (en) | 2011-11-11 | 2018-02-21 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
US20150184246A1 (en) | 2011-11-11 | 2015-07-02 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
CA2856107C (en) | 2011-11-18 | 2022-10-18 | Memorial Sloan-Kettering Cancer Center | 2-hydroxyglutarate as a biomarker for chronic hypoxia |
US8748097B1 (en) | 2011-12-02 | 2014-06-10 | President And Fellows Of Harvard College | Identification of agents for treating calcium disorders and uses thereof |
WO2013087789A1 (en) | 2011-12-13 | 2013-06-20 | Glykos Finland Ltd. | Antibody isoform arrays and methods thereof |
CA2864300A1 (en) | 2012-02-16 | 2013-08-22 | Atyr Pharma, Inc. | Histidyl-trna synthetases for treating autoimmune and inflammatory diseases |
EP2827882B1 (en) | 2012-02-21 | 2020-04-08 | Cytonics Corporation | Systems, compositions, and methods for transplantation |
EP2820174B1 (en) | 2012-02-27 | 2019-12-25 | The University of North Carolina at Chapel Hill | Methods and uses for molecular tags |
EP3321378B1 (en) | 2012-02-27 | 2021-11-10 | Becton, Dickinson and Company | Compositions for molecular counting |
CN104379764B (en) | 2012-03-28 | 2018-04-06 | 私募蛋白质体公司 | PDGF and VEGF fit and their purposes in the symptom for the treatment of PDGF and VEGF mediations |
WO2014007623A1 (en) | 2012-07-03 | 2014-01-09 | Interna Technologies B.V. | Diagnostic portfolio and its uses |
EP3309263B1 (en) | 2012-07-09 | 2019-12-25 | Novartis AG | Biomarkers associated with cdk inhibitors |
SI2880447T1 (en) | 2012-07-31 | 2019-09-30 | Novartis Ag | Markers associated with sensitivity to inhibitors of human double minute 2 (mdm2) |
EP2904115B1 (en) | 2012-10-01 | 2018-08-08 | Millennium Pharmaceuticals, Inc. | Biomarkers and methods to predict response to inhibitors and uses thereof |
WO2014055117A1 (en) | 2012-10-04 | 2014-04-10 | Asuragen, Inc. | Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions |
US20150354006A1 (en) | 2012-10-19 | 2015-12-10 | Novartis Ag | Markers for acute lymphoblastic leukemia |
EP2925886B1 (en) | 2012-11-27 | 2019-04-24 | Pontificia Universidad Católica de Chile | Compositions and methods for diagnosing thyroid tumors |
BR112015012295A8 (en) | 2012-11-28 | 2023-03-14 | Merck Sharp & Dohme | USE OF A WEE1 INHIBITOR, E, KIT TO IDENTIFY A PATIENT WITH CANCER |
WO2014113204A1 (en) | 2013-01-17 | 2014-07-24 | Personalis, Inc. | Methods and systems for genetic analysis |
EP2953970A4 (en) | 2013-02-08 | 2016-06-29 | Misfolding Diagnostics Inc | Transthyretin antibodies and uses thereof |
TWI582239B (en) | 2013-03-11 | 2017-05-11 | 諾華公司 | Markers associated with wnt inhibitors |
WO2014159242A1 (en) | 2013-03-14 | 2014-10-02 | Novartis Ag | Notch 3 mutants and uses thereof |
EP2970479B1 (en) | 2013-03-14 | 2019-04-24 | Novartis AG | Antibodies against notch 3 |
EP3404116B1 (en) | 2013-03-15 | 2022-10-19 | The University of Chicago | Methods and compositions related to t-cell activity |
EP2971149B1 (en) | 2013-03-15 | 2018-05-09 | Baylor Research Institute | Ulcerative colitis (uc)-associated colorectal neoplasia markers |
US10535420B2 (en) | 2013-03-15 | 2020-01-14 | Affymetrix, Inc. | Systems and methods for probe design to detect the presence of simple and complex indels |
EP2971132B1 (en) | 2013-03-15 | 2020-05-06 | Baylor Research Institute | Tissue and blood-based mirna biomarkers for the diagnosis, prognosis and metastasis-predictive potential in colorectal cancer |
US20160091485A1 (en) | 2013-04-25 | 2016-03-31 | The Broad Institute, Inc. | Markers for ezh2 inhibitors |
WO2014195032A1 (en) | 2013-06-07 | 2014-12-11 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients |
WO2015031654A2 (en) | 2013-08-28 | 2015-03-05 | Cytonics Corporation | Systems, compositions, and methods for transplantation and treating conditions |
KR102536833B1 (en) | 2013-08-28 | 2023-05-26 | 벡톤 디킨슨 앤드 컴퍼니 | Massively parallel single cell analysis |
EP3965111A1 (en) | 2013-08-30 | 2022-03-09 | Personalis, Inc. | Methods and systems for genomic analysis |
JP6111941B2 (en) * | 2013-09-06 | 2017-04-12 | 日本軽金属株式会社 | Biochip substrate |
JP6630273B2 (en) | 2013-09-09 | 2020-01-15 | ソマロジック・インコーポレーテッド | PDGF and VEGF aptamers with improved stability and their use in the treatment of PDGF and VEGF mediated diseases and disorders |
US20150098940A1 (en) | 2013-10-03 | 2015-04-09 | Oklahoma Medical Research Foundation | Biomarkers for Systemic Lupus Erythematosus Disease Activity, and Intensity and Flare |
GB2535066A (en) | 2013-10-03 | 2016-08-10 | Personalis Inc | Methods for analyzing genotypes |
US20160304969A1 (en) | 2013-12-17 | 2016-10-20 | Merck Sharp & Dohme Corp. | Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonists |
EP3102701A1 (en) | 2014-02-07 | 2016-12-14 | Novartis AG | Impact of genetic factors on disease progression and response to anti-c5 antibody in geographic atrophy |
US9153357B1 (en) * | 2014-03-27 | 2015-10-06 | Rohm And Haas Electronic Materials Llc | Adhesion promoter |
US9136037B1 (en) * | 2014-03-27 | 2015-09-15 | Rohm And Haas Electronic Materials Llc | Adhesion promoter |
WO2016008048A1 (en) | 2014-07-15 | 2016-01-21 | Ontario Institute For Cancer Research | Methods and devices for predicting anthracycline treatment efficacy |
US10093967B2 (en) | 2014-08-12 | 2018-10-09 | The Regents Of The University Of Michigan | Detection of nucleic acids |
WO2016038550A1 (en) | 2014-09-11 | 2016-03-17 | Novartis Ag | Inhibition of prmt5 to treat mtap-deficiency-related diseases |
EP4026913A1 (en) | 2014-10-30 | 2022-07-13 | Personalis, Inc. | Methods for using mosaicism in nucleic acids sampled distal to their origin |
US10479997B2 (en) | 2014-12-01 | 2019-11-19 | Novartis Ag | Compositions and methods for diagnosis and treatment of prostate cancer |
JP6759229B2 (en) | 2014-12-08 | 2020-09-23 | バーグ エルエルシー | Use of markers containing filamin A in the diagnosis and treatment of prostate cancer |
RU2017123117A (en) | 2014-12-09 | 2019-01-10 | Мерк Шарп И Доум Корп. | SYSTEM AND METHODS FOR PRODUCING BIOMARKERS OF GENE SIGNATURES OF RESPONSE TO PD-1 ANTAGONISTS |
EP3283882B1 (en) | 2015-04-17 | 2020-12-16 | Merck Sharp & Dohme Corp. | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists |
DK3245517T3 (en) | 2015-10-07 | 2019-01-14 | Selma Diagnostics Aps | Flow system and method for digital counting |
EP3362580B1 (en) | 2015-10-18 | 2021-02-17 | Affymetrix, Inc. | Multiallelic genotyping of single nucleotide polymorphisms and indels |
US11299783B2 (en) | 2016-05-27 | 2022-04-12 | Personalis, Inc. | Methods and systems for genetic analysis |
GB2600627B (en) | 2016-05-27 | 2022-12-07 | Personalis Inc | Personalized genetic testing |
US20200185063A1 (en) | 2016-06-05 | 2020-06-11 | Berg Llc | Systems and methods for patient stratification and identification of potential biomarkers |
WO2018137705A1 (en) | 2017-01-26 | 2018-08-02 | Zai Lab (Shanghai) Co., Ltd. | Cd47 antigen binding unit and uses thereof |
CN110462062A (en) | 2017-01-26 | 2019-11-15 | 俄克拉荷马医学研究基金会 | Systemic loupus erythematosus Disease Activity, intensity and the biomarker of acute attack |
WO2018163051A1 (en) | 2017-03-06 | 2018-09-13 | Novartis Ag | Methods of treatment of cancer with reduced ubb expression |
EP3375889B1 (en) | 2017-03-17 | 2019-12-11 | HiFiBiO SAS | Single cell analysis |
JP2020517715A (en) | 2017-04-28 | 2020-06-18 | メルク・シャープ・エンド・ドーム・コーポレイション | Biomarkers for cancer therapy |
WO2018213803A1 (en) | 2017-05-19 | 2018-11-22 | Neon Therapeutics, Inc. | Immunogenic neoantigen identification |
WO2019016772A2 (en) | 2017-07-21 | 2019-01-24 | Novartis Ag | Compositions and methods to treat cancer |
US11497762B2 (en) | 2017-11-03 | 2022-11-15 | Interna Technologies B.V. | MiRNA molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation |
US20200377958A1 (en) | 2017-12-01 | 2020-12-03 | Millennium Pharmaceuticals, Inc. | Biomarkers and methods for treatment with nae inhibitors |
WO2019213276A1 (en) | 2018-05-02 | 2019-11-07 | Novartis Ag | Regulators of human pluripotent stem cells and uses thereof |
US11814750B2 (en) | 2018-05-31 | 2023-11-14 | Personalis, Inc. | Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples |
US10801064B2 (en) | 2018-05-31 | 2020-10-13 | Personalis, Inc. | Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples |
WO2020081204A1 (en) | 2018-10-18 | 2020-04-23 | Oklahoma Medical Research Foundation | Biomarkers for a systemic lupus erythematosus (sle) disease activity immune index that characterizes disease activity |
MX2021006234A (en) | 2018-11-30 | 2021-09-10 | Caris Mpi Inc | Next-generation molecular profiling. |
CA3127113A1 (en) | 2019-01-30 | 2020-08-06 | Dongxu Sun | Anti-gal3 antibodies and uses thereof |
US20220162198A1 (en) | 2019-04-12 | 2022-05-26 | The Regents Of The University Of California | Compositions and methods for increasing muscle mass and oxidative metabolism |
KR20220015394A (en) | 2019-04-30 | 2022-02-08 | 라리마 테라퓨틱스, 인코포레이티드 | Frataxin sensitivity markers for determining the efficacy of prataxin replacement therapy |
CN110066861A (en) * | 2019-05-05 | 2019-07-30 | 南京拓远生物科技有限公司 | A kind of patterning microarray flow cell, production method, detection method and its application |
MX2021015058A (en) | 2019-06-07 | 2022-04-06 | Scribe Therapeutics Inc | Engineered casx systems. |
US20220348925A1 (en) | 2019-09-09 | 2022-11-03 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of sod1 |
CN114729368A (en) | 2019-09-09 | 2022-07-08 | 斯克里贝治疗公司 | Compositions and methods for immunotherapy |
IL293489A (en) | 2019-12-02 | 2022-08-01 | Caris Mpi Inc | Pan-cancer platinum response predictor |
CA3159316A1 (en) | 2019-12-06 | 2021-06-10 | Benjamin OAKES | Compositions and methods for the targeting of rhodopsin |
EP4069846A1 (en) | 2019-12-07 | 2022-10-12 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of htt |
KR20220125332A (en) | 2020-01-10 | 2022-09-14 | 스크라이브 테라퓨틱스 인크. | Compositions and methods for targeting PCSK9 |
EP4121535A1 (en) | 2020-03-18 | 2023-01-25 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of c9orf72 |
WO2022047359A1 (en) | 2020-08-31 | 2022-03-03 | Berg Llc | Protein biomarkers for pancreatic cancer |
EP4256054A1 (en) | 2020-12-03 | 2023-10-11 | Scribe Therapeutics Inc. | Engineered class 2 type v crispr systems |
WO2022120089A1 (en) | 2020-12-03 | 2022-06-09 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of ptbp1 |
WO2022216846A1 (en) | 2021-04-06 | 2022-10-13 | Berg Llc | Protein markers for estrogen receptor (er)-positive-like and estrogen receptor (er)-negative-like breast cancer |
WO2022216841A1 (en) | 2021-04-06 | 2022-10-13 | Berg Llc | Protein markers for estrogen receptor (er)-positive luminal a(la)-like and luminal b1 (lb1)-like breast cancer |
CA3214833A1 (en) | 2021-04-06 | 2022-10-13 | Bpgbio, Inc. | Protein markers for the prognosis of breast cancer progression |
WO2023196937A1 (en) | 2022-04-06 | 2023-10-12 | Larimar Therapeutics, Inc. | Frataxin-sensitive markers for monitoring frataxin replacement therapy |
WO2023235818A2 (en) | 2022-06-02 | 2023-12-07 | Scribe Therapeutics Inc. | Engineered class 2 type v crispr systems |
WO2023240074A1 (en) | 2022-06-07 | 2023-12-14 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of pcsk9 |
EP4314267A1 (en) | 2022-06-07 | 2024-02-07 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of pcsk9 |
WO2023240201A1 (en) | 2022-06-08 | 2023-12-14 | Larimar Therapeutics, Inc. | Frataxin-sensitive markers for monitoring progression and treatment of leigh syndrome |
WO2024028794A1 (en) | 2022-08-02 | 2024-02-08 | Temple Therapeutics BV | Methods for treating endometrial and ovarian hyperproliferative disorders |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991007087A1 (en) * | 1989-11-13 | 1991-05-30 | Affymax Technologies N.V. | Spatially-addressable immobilization of anti-ligands on surfaces |
US5143854A (en) * | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4282287A (en) * | 1980-01-24 | 1981-08-04 | Giese Roger W | Biochemical avidin-biotin multiple-layer system |
GB8314523D0 (en) * | 1983-05-25 | 1983-06-29 | Lowe C R | Diagnostic device |
US4542102A (en) * | 1983-07-05 | 1985-09-17 | Molecular Diagnostics, Inc. | Coupling of nucleic acids to solid support by photochemical methods |
US4681870A (en) * | 1985-01-11 | 1987-07-21 | Imre Corporation | Protein A-silica immunoadsorbent and process for its production |
US4937188A (en) * | 1986-04-15 | 1990-06-26 | Northeastern University | Enzyme activity amplification method for increasing assay sensitivity |
US4762881A (en) * | 1987-01-09 | 1988-08-09 | E. I. Du Pont De Nemours And Company | Photoreactive benzoylphenylalanines and related peptides |
US5077085A (en) * | 1987-03-06 | 1991-12-31 | Schnur Joel M | High resolution metal patterning of ultra-thin films on solid substrates |
US5079600A (en) * | 1987-03-06 | 1992-01-07 | Schnur Joel M | High resolution patterning on solid substrates |
US5011770A (en) * | 1987-09-04 | 1991-04-30 | Molecular Devices, Inc. | DNA detection method |
JP2897959B2 (en) * | 1988-05-20 | 1999-05-31 | エフ.ホフマン―ラ ロシュ アクチェンゲゼルシャフト | Immobilized sequence-specific probe |
US5237016A (en) * | 1989-01-05 | 1993-08-17 | Siska Diagnostics, Inc. | End-attachment of oligonucleotides to polyacrylamide solid supports for capture and detection of nucleic acids |
US5077210A (en) * | 1989-01-13 | 1991-12-31 | Eigler Frances S | Immobilization of active agents on substrates with a silane and heterobifunctional crosslinking agent |
WO1991000868A1 (en) * | 1989-07-07 | 1991-01-24 | National Research Development Corporation | Immobilised polynucleotides |
GB2233654A (en) * | 1989-07-07 | 1991-01-16 | Nat Res Dev | Immobilised polynucleotides |
PT96458B (en) * | 1990-01-10 | 1998-06-30 | Chiron Corp | USE OF TRANSCRIPTS OF DNA DEPENDENT POLYMERASE RNA AS REGISTERING MOLECULES FOR SIGNAL AMPLIFICATION IN NUCLEIC ACID HYBRIDIZATION TESTS |
US5324633A (en) * | 1991-11-22 | 1994-06-28 | Affymax Technologies N.V. | Method and apparatus for measuring binding affinity |
US5288514A (en) * | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
-
1992
- 1992-04-24 US US07/874,849 patent/US5412087A/en not_active Expired - Lifetime
-
1993
- 1993-04-21 WO PCT/US1993/003767 patent/WO1993022680A1/en active Application Filing
- 1993-04-21 AU AU41107/93A patent/AU4110793A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5143854A (en) * | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
WO1991007087A1 (en) * | 1989-11-13 | 1991-05-30 | Affymax Technologies N.V. | Spatially-addressable immobilization of anti-ligands on surfaces |
Non-Patent Citations (1)
Title |
---|
SCIENCE, Volume 251, issued 15 February 1991, FODOR et al., "Light-Directed Spatially Addressable Parallel Chemical Synthesis", pages 767-773. * |
Cited By (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6080585A (en) * | 1994-02-01 | 2000-06-27 | Oxford Gene Technology Limited | Methods for discovering ligands |
WO1995021265A1 (en) * | 1994-02-01 | 1995-08-10 | Isis Innovation Limited | Methods for discovering ligands |
EP0764214A1 (en) * | 1994-06-08 | 1997-03-26 | Affymax Technologies N.V. | Bioarray chip reaction apparatus and its manufacture |
EP0764214A4 (en) * | 1994-06-08 | 1997-05-07 | ||
EP0913485A1 (en) * | 1994-06-17 | 1999-05-06 | The Board Of Trustees Of The Leland Stanford Junior University | Method and apparatus for fabricating microarrays of biological samples |
EP0804731A1 (en) * | 1994-06-17 | 1997-11-05 | The Board Of Trustees Of The Leland Stanford Junior University | Method and apparatus for fabricating microarrays of biological samples |
EP0804731A4 (en) * | 1994-06-17 | 1997-11-26 | ||
AU709276B2 (en) * | 1994-06-17 | 1999-08-26 | Board Of Trustees Of The Leland Stanford Junior University | Method and apparatus for fabricating microarrays of biological samples |
US5807522A (en) * | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
EP0952216A2 (en) * | 1994-10-13 | 1999-10-27 | Lynx Therapeutics, Inc. | Solid phase supports with PNA and amidate tag compliments |
US6138077A (en) * | 1994-10-13 | 2000-10-24 | Lynx Therapeutics, Inc. | Method, apparatus and computer program product for determining a set of non-hybridizing oligonucleotides |
USRE43097E1 (en) | 1994-10-13 | 2012-01-10 | Illumina, Inc. | Massively parallel signature sequencing by ligation of encoded adaptors |
EP2110445A3 (en) * | 1994-10-13 | 2010-06-02 | Solexa, Inc. | Molecular tagging system |
US5695934A (en) * | 1994-10-13 | 1997-12-09 | Lynx Therapeutics, Inc. | Massively parallel sequencing of sorted polynucleotides |
US5635400A (en) * | 1994-10-13 | 1997-06-03 | Spectragen, Inc. | Minimally cross-hybridizing sets of oligonucleotide tags |
EP0952216A3 (en) * | 1994-10-13 | 2000-01-19 | Lynx Therapeutics, Inc. | Solid phase supports with PNA and amidate tag compliments |
EP1724348A3 (en) * | 1994-10-13 | 2008-10-08 | Solexa, Inc. | Solid phase supports with PNA and amidate tag compliments |
US5604097A (en) * | 1994-10-13 | 1997-02-18 | Spectragen, Inc. | Methods for sorting polynucleotides using oligonucleotide tags |
US5863722A (en) * | 1994-10-13 | 1999-01-26 | Lynx Therapeutics, Inc. | Method of sorting polynucleotides |
US6140489A (en) * | 1994-10-13 | 2000-10-31 | Lynx Therapeutics, Inc. | Compositions for sorting polynucleotides |
USRE39793E1 (en) | 1994-10-13 | 2007-08-21 | Solexa, Inc. | Compositions for sorting polynucleotides |
US6172214B1 (en) | 1994-10-13 | 2001-01-09 | Lynx Therapeutics, Inc. | Oligonucleotide tags for sorting and identification |
US6172218B1 (en) | 1994-10-13 | 2001-01-09 | Lynx Therapeutics, Inc. | Oligonucleotide tags for sorting and identification |
US6235475B1 (en) | 1994-10-13 | 2001-05-22 | Lynx Therapeutics, Inc. | Oligonucleotide tags for sorting and identification |
US6280935B1 (en) | 1994-10-13 | 2001-08-28 | Lynx Therapeutics, Inc. | Method of detecting the presence or absence of a plurality of target sequences using oligonucleotide tags |
EP1724348A2 (en) | 1994-10-13 | 2006-11-22 | Solexa, Inc. | Molecular tagging system |
US6352828B1 (en) | 1994-10-13 | 2002-03-05 | Lynx Therapeutics, Inc. | Oligonucleotide tags for sorting and identification |
US7138268B2 (en) | 1995-03-28 | 2006-11-21 | Agilent Technologies, Inc. | Dry biochemical assay plate and method for making the same |
US7083917B2 (en) | 1996-02-09 | 2006-08-01 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
US8288521B2 (en) | 1996-02-09 | 2012-10-16 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
US9234241B2 (en) | 1996-02-09 | 2016-01-12 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
EP0920440A4 (en) * | 1996-02-09 | 2004-08-25 | Cornell Res Foundation Inc | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
US6852487B1 (en) | 1996-02-09 | 2005-02-08 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
US9206477B2 (en) | 1996-02-09 | 2015-12-08 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
US8703928B2 (en) | 1996-02-09 | 2014-04-22 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
US8624016B2 (en) | 1996-02-09 | 2014-01-07 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
EP2574617A1 (en) * | 1996-02-09 | 2013-04-03 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
EP2573101A1 (en) * | 1996-02-09 | 2013-03-27 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
EP2368897A1 (en) * | 1996-02-09 | 2011-09-28 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
EP2332958A1 (en) * | 1996-02-09 | 2011-06-15 | Cornell Research Foundation, Inc. | Detection of nucleic and sequence differences using the ligase detection reaction with addressable arrays |
EP2332957A1 (en) * | 1996-02-09 | 2011-06-15 | Cornell Research Foundation, Inc. | Detection of nucleic and acid sequence differences using the ligase detection reaction with addressable arrays |
US7914981B2 (en) | 1996-02-09 | 2011-03-29 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
US7893233B2 (en) | 1996-02-09 | 2011-02-22 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
US7892747B2 (en) | 1996-02-09 | 2011-02-22 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
US7892746B2 (en) | 1996-02-09 | 2011-02-22 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
US7888009B2 (en) | 1996-02-09 | 2011-02-15 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
EP1958955A1 (en) * | 1996-02-09 | 2008-08-20 | Cornell Research Foundation, Inc. | Spatially addressable oligonucleotide arrays and method of making the same |
EP0920440A2 (en) * | 1996-02-09 | 1999-06-09 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
US7166434B2 (en) | 1996-05-29 | 2007-01-23 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions |
US7097980B2 (en) | 1996-05-29 | 2006-08-29 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions |
US7429453B2 (en) | 1996-05-29 | 2008-09-30 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions |
US7364858B2 (en) | 1996-05-29 | 2008-04-29 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions |
US7332285B2 (en) | 1996-05-29 | 2008-02-19 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions |
US7320865B2 (en) | 1996-05-29 | 2008-01-22 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions |
US7312039B2 (en) | 1996-05-29 | 2007-12-25 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions |
US5858666A (en) * | 1996-08-29 | 1999-01-12 | Biotechnology Research And Development Corporation | Apparatus and method of detection employing an AC frequency sensor array |
US6576752B1 (en) | 1997-02-14 | 2003-06-10 | Isis Pharmaceuticals, Inc. | Aminooxy functionalized oligomers |
US8140148B2 (en) | 1998-01-20 | 2012-03-20 | Boston Scientific Scimed Ltd. | Readable probe array for in vivo use |
DE19853640C2 (en) * | 1998-11-20 | 2002-01-31 | Molecular Machines & Ind Gmbh | Multi-vessel arrangement with improved sensitivity for optical analysis, processes for its production and its use in optical analysis processes |
DE19853640A1 (en) * | 1998-11-20 | 2000-06-08 | Molecular Machines & Ind Gmbh | Multi-vessel arrangement with improved sensitivity for optical analysis |
US7932213B2 (en) | 1999-05-11 | 2011-04-26 | President And Fellows Of Harvard College | Small molecule printing |
WO2001001142A2 (en) * | 1999-06-29 | 2001-01-04 | Chiron Corporation | Arrays of biopolymeric agents and method for their production and use |
WO2001001142A3 (en) * | 1999-06-29 | 2001-08-30 | Chiron Corp | Arrays of biopolymeric agents and method for their production and use |
US7455965B2 (en) | 2000-04-14 | 2008-11-25 | Cornell Research Foundation, Inc. | Method of designing addressable array for detection of nucleic acid sequence differences using ligase detection reaction |
US8492085B2 (en) | 2000-04-14 | 2013-07-23 | Cornell Research Foundation, Inc. | Method of designing addressable array suitable for detection of nucleic acid sequence differences using ligase detection reaction |
US9340834B2 (en) | 2000-04-14 | 2016-05-17 | Cornell Research Foundation, Inc. | Method of designing addressable array suitable for detection of nucleic acid sequence differences using ligase detection reaction |
US9725759B2 (en) | 2000-04-14 | 2017-08-08 | Cornell Research Foundation, Inc. | Method of designing addressable array suitable for detection of nucleic acid sequence differences using ligase detection reaction |
US10131938B2 (en) | 2000-04-14 | 2018-11-20 | Cornell Research Foundation, Inc. | Method of designing addressable array suitable for detection of nucleic acid sequence differences using ligase detection reaction |
EP1421201A2 (en) * | 2001-07-31 | 2004-05-26 | New York Institute Of Technology | Methods for immobilizing molecules to a solid phase and uses thereof |
EP1421201A4 (en) * | 2001-07-31 | 2005-11-23 | New York Inst Techn | Methods for immobilizing molecules to a solid phase and uses thereof |
US7195872B2 (en) | 2001-11-09 | 2007-03-27 | 3D Biosurfaces, Inc. | High surface area substrates for microarrays and methods to make same |
DE10260431B4 (en) * | 2002-12-21 | 2006-05-04 | Forschungszentrum Jülich GmbH | Method for self-aligning immobilization of living cells on a silicon-based substrate |
DE10260431A1 (en) * | 2002-12-21 | 2004-07-01 | Forschungszentrum Jülich GmbH | Self-justifying immobilization of living cells on a silicon substrate, useful in preparation of sensors, by attaching mutually interacting molecules to surfaces of cells and substrate |
Also Published As
Publication number | Publication date |
---|---|
AU4110793A (en) | 1993-11-29 |
US5412087A (en) | 1995-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5412087A (en) | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces | |
KR970001577B1 (en) | Very large scale immobilized peptide synthesis | |
US6610482B1 (en) | Support bound probes and methods of analysis using the same | |
US6379895B1 (en) | Photolithographic and other means for manufacturing arrays | |
US6919211B1 (en) | Polypeptide arrays | |
US5252743A (en) | Spatially-addressable immobilization of anti-ligands on surfaces | |
JP2002535013A (en) | Replicatable probe array | |
US20050064494A1 (en) | Chemically modified biological molecules and methods for coupling biological molecules to solid support | |
JP2006227017A (en) | Method for reducing non-specific binding to nucleic acid probe array | |
EP0502060A4 (en) | Spatially-addressable immobilization of anti-ligands on surfaces | |
KR20010001577A (en) | Process for Preparing Oligopeptidenucleotide Probe Using Polymeric Photoacid Generator | |
US20060194258A1 (en) | Polypeptide array synthesis | |
JP3857075B2 (en) | Reactive solid phase carrier and DNA fragment detection tool |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |